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Introduction
1. INTRODUCTION
     Ideal drug delivery systems deliver the drug at a rate dictated by the need of
the body over the period of treatment and it channels the activity entirely solely to the
site of action. At present no available drug delivery systems can achieve all  these
goals1. 
1.1. TARGETTED DRUG DELIVERY SYSTEM
The nanotechnology carrier main advantage for site specific or organ specific
particulate drug carrier include microparticulate, nanocarriers, lipid based carriers and
colloidal carriers this drug carrier needs some special character and limitation.
1.2. LEVELS OF DRUG TARGETING 
             The drug delivery in colloidal carriers paves way for targeting drugs to
specific  sites.  The  various  mechanism involved  in  drug  reach  to  specific  site  as
follows2,
a) Passive target
b) Active target                                                                               
                     i)  First order targeting
                     ii) Second order targeting
                    iii) Third order targeting
c) Legend mediated targeting
d) Physical targeting
e) Dual targeting
f) Double targeting
g) Combination targeting
 
a) PASSIVE TARGETING
     In  passive targeting the  particles  system is  captured by physiological
uptake mechanism such as filtration or macrophage (RES) sequestration. Then
the passive involved for drug concentration in plasma and blood levels. The
passive targeting is  concentration dependent.  So, they do not need external
energy.
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b) ACTIVE TARGETING
The  active  targeting  is  attachment  of  a  main  moiety  in  particles
surface.  Such  as  monoclonal  antibodies  or  carbohydrate  like  glucose,
galactose, glucose-6-phosphate. The role of an ideal carrier is to transport the
required amount of drug to a highly specific site. Which may be organ, tissue
or  organneller  related,  the  carrier  also  having  property  of  accumulate  at
specific receptors and specific organeller with the cells.
i)  FIRST ORDER TARGETING
The first order targeting means delivery of drug to a particular organ. The first
order targeting more effective on selection of carrier.
ii) SECOND ORDER TARGETING
The second order targeting to a specific cell type. This method widely used for
the    particular therapeutic purpose.
iii) THIRD ORDER TARGETING
Third  order  targeting  based  on  a  structure  within  a  cell.  The  third  order
targeting is essential for gene delivery and targeting of an exogenous DNA to the
nucleolus. It is prerequisite for gene expression. The active targeting more specific
for kupffer cells of the liver and parenchymal cells like hepatocytes.
c) LEGEND MEDIATED TARGETING
In  this  method  the  drug  molecules  incorporated  with  lipo-proteins.  The  lipo-
proteins from natural or synthetic origin and they have low density. The carrier
molecules having lipo-protein nature. So, they easily modified their structure and
accumulate the specific target like origin, tissue and organelles site.
d)PHYSICAL TARGETING
The  physical  targeting  based  on  external  levels  (ex-vivo).  The  physical
targeting basic mechanism is drug release from the carrier on external condition
or environment EX, The thermo-sensitive nanoparticles may be used for selective
release of the content after specific localization like photodynamic therapy EX,
doxorubicin nanoparticles.
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e) DUAL TARGETING
Dual  targeting  means,  the  drug  molecules  having  more  specific
synergistic  force  with  specific  organs  or  tissues.  The  nano  formulation  to
extend the half life of the drug molecules and it will enhance the penetration of
drug in cell membrane.
f) DOUBLE TARGETING
  Double targeting means, the drug molecules reached to specific site by
active and passive mechanism. The specific site targeting of drug molecules
based on selection of suitable carrier. The combination made with spatial and
temporal control of drug delivery.
   
g) COMBINATION TARGETING
       The combination targeting for  site  specific  delivery of  proteins  and
peptides. The targeting systems are equipped with carrier and polymer. This
method more specific for the gene therapy.
            
1.3. NEED OF VESICULAR, COLLAIDAL, MICRO AND NANOCARRIER 3:
 Better drug delivery to certain stubborn or impermeable of body.
 Owing to  their  small  size,  chemistry and  distribution  these  carriers  have
better Bridged gaps between and function of biomolecules.
 Reaching of micron or nano range with these particles enables them to be a
Highly potential carrier in many biological molecules as proteins. e.g., DNA,
viruses and xenobiotics.
 Better targeting to body tissues and sites where action is required, elimination
of side effects and adverse effects.
 Owing  to  size,  nature  and  chemistry,  these  systems  give  better  drug
permeability from biological membranes and helps in solubilization of some
practically insoluble drugs and hence solve bioavailability problems of many
drugs.
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  It involves overlap of biotech, and information technology, might result in
many important application in life science including area of gene therapy,
drug delivery, imaging, biomarkers and novel drug discovery techniques.
  It  also offers an attractive solution for transformation of bio-systems, and
provide a broad platform in several areas of bioscience.
 The surface properties of carrier can be modified for targeted drug delivery
e.g.  small  molecules,  proteins,  peptides  and  nucleic  acids  loaded
nanoparticles are not recognized by immune systems and efficiently targeted
to particular tissue types.
 Targeted drug carriers reduce drug toxicity and provide more efficient drug
distribution. The drug carrier to enhance half life of the drug molecule and
increase in bio-distribution.
  Drug carriers better  penetrate tumors due to their  constitution containing
pores ranging from 100- 1000 nm in diameter, sometime liphophilic nature
carrier used for nanoparticles formulation enhance the penetration nature of
drug targeted site.                                                                 
       
LIMITATION:
● Drug carriers  exhibits  difficulty in  handling,  storage,  and  administration
because of susceptibility to aggregation.
● It has unsuitability for less potent drugs. 
● But the key of concern is related to its small size as nanocarriers can gain
access to unintended environments with harmful consequences e.g., It can
cross the nuclear envelope of a cell and cause unintended genetic damage
and mutations. 
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Table 1. VARIOUS CARRIER BASED DOSAGE FORMS3
S.NO Carrier system Size range Feature Method preparation
1
    
Nanoparticles  10-1000nm 
  
   Submicron-     sized
colloidal systems, 
  Biodegradable or not 
                                       
                                  
2
      
Solid  lipid
nanoparticle 
 
 50-1000nm 
 
 Submicron  colloidal
carriers  containing  solid
hydrophobic core having
a  monolayer  of 
phospholipids coating. 
  
High-pressure
homogenization 
  Microemulsion
formation 
  Precipitation 
  As lipid nanopellets 
3
   
 Polymeric
nanoparticle 
  
10-1000nm 
   
Sub-nanosized  colloidal
structures  composed  of
synthetic  or  semi-
synthetic polymers 
  
4
   
 Ceramic
nanoparticle 
    
 <50nm 
   
 Made  up  of  inorganic
(ceramic)  compounds
such as silica, titania and
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alumina. 
5
    
 Nanotubes  and
Nanowires 
     
Self-assembling  sheet  of
atoms  arranged  in  the
form of tubes and thread-
like  structures  of
nanoscale range 
Surface
functionalization 
6
  
Functionalized
Nanocarriers/
Quantam dots 
         
Combination  of
functionalities  of
biomolecules  and  non-
biologically  derived
molecular species 
  
7
  
Liposomes 
 
25nm-100µm 
    
 Microscopic  vesicles
composed of one or more
concentric  lipid  bilayers,
separated  by  water  or
aqueous  buffer
compartments 
  
Mechanical dispersion 
  Solvent dispersion 
  Detergent removal 
8 Lipid emulsion Lipid  globules   
1-100nm 
Multicomponent  fluid
made of water, 
       o/w 
       w/o 
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  A hydrophobic liquid,
   One  or  several
surfactants resulting in a
stable system 
       w/o/w 
        w/o/o 
9 Lipidmicrotubules
/ microcylinders 
<1µm 
   Self organizing system
in  which  surfactants
crystallize  into  tightly
packed  bi  layers  that
spontaneously  form
  
Self emulsification 
10 Lipid
microbubbles 
Few microns     Gas  filled
microspheres  stabilised
by phospholipids.
   Sonication 
11 Lipospheres 0.2-100µm 
  
 Water  dispersible
solidmicro  particles
composed  of  solid
hydrophobic  fat  core
stabilized by a monolayer
of  phospholipids
molecules embedded in a
microparticle surface 
  Melt method 
  Multiple
microemulsion 
Cosolvent method 
Preincorporation  into
lipophilic carrier 
12
 
 Ethosomes 
-   Noninvasive  delivery
carriers that enable drugs
to  reach  the  deep  skin
layers  and/or  the
systemic circulation 
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13
 
 Multicomposite
ultrathin capsules 
50nm  to  few
micron 
  Molecular assemblies of
tailored  architecture
having  layer-by-layer
adsorption  of  oppositely
charged  macromolecules
onto colloidal particle 
Langmuir-Blodgelt
technique  and
chemiosorption  from
solution 
14
  Aquasomes   60-300nm   The  particle  core  is
composed  of
noncrystalline  calcium
phosphate  or  ceramic
diamond, and is covered
  
        Self-assemblin
hydroxyapatite  by    
co-precipitation method
15 Pharmacosomes   Pure  drug  vesicles
formed  by  the
Amphiphilic drugs 
  
16 Dendrimers 
 
Macromolecular
compounds  that  consist
of  a  series  of  branches
around an inner core 
  
Polymerization 
17 Colloidosomes 
- 
Solid  microcapsules
which are hollow, elastic
shells 
Self-assembly  of
colloidal particles at the
interface  of  emulsion
droplets 
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18 Niosomes 
10 to 1000 nm 
Non-ionic  surfactant   
vesicles  are  bilayered
structures 
  
1.4. PRIMARY GOALS OF NANO BIO – TECHNOLOGIES3:
More specific drug targeting drug delivery,
Reduction in toxicity while maintaining therapeutic effects,
Greater safety and biocompatibility,
Faster development of new medicine.
1.5.   NANOPARTICLES   INTRODUCTION
             Nanoparticles are the simplest form of structures with sizes in the nm range.
In principle any collection of atoms bonded together with a structural radius of < 100
nm can be considered a nanoparticle.
           These can include, e.g., fullerens, metal clusters (agglomerates of metal atoms),
large molecules,  such as  proteins,  and even hydrogen-bonded assemblies  of  water
molecules, which exist in water at ambient temperatures.
 Nanoparticles are very commonplace in nature - for instance proteins exist in
almost all biological systems, metal-oxide nanoparticles are easily produced, etc.,  
Size Ranges of Particle
● Coarse particles: >10µm
● Fine particles: ~1 µm
● Ultrafine (nano) particles: <0.1  (100nm)
ADVANTAGES OF FEATURE OF NANOPARTICLES4
 Bioavailability
 Dose proportionality
 Decreased toxicity
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 Smaller dosage form (i.e., smaller tablet)
 Stable dosage forms of drugs which are either unstable or have unacceptably
low bioavailability in non-nanoparticle dosage forms
 Increased active agent surface area result in a faster dissolution of the active
agent in an aqueous environment, such as the human body, faster dissolution
generally equates with greater bioavailability, smaller drug doses, less toxicity
 Controlled rate of drug release,
 Greater patient convenience and or better patient compliance,
 Easy handling of nanoparticles prepared in the powder form,
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1.6. NANOTECHNOLOGY IN MEDICINE: THERAPEUTIC APPLICATION
AND DEVELOPMENTS 5
       The  application  of  nanotechnology  to  medicine,  known as  nanomedicine,
concerns  the use  of  precisely engineered materials  at  this  length  scale to  develop
novel therapeutic and diagnostic modalities. 
       The  use  of  materials  in  nanoscale  provides  unparallel  freedom to  modify
fundamental properties such as solubility, diffusivity, blood circulation half-life, drug
release characteristics,  and  immunogenicity.  In  the last  two decades,  a  number  of
nanoparticles-based  therapeutic  and  diagnostic  agents  have  been  developed  for
treatment of cancer, diabetes,  pain,  asthma,  allergy,  infection, and so on. Many
advantages of nanoparticle-based drug delivery have been recognized. It  improvers
the solubility of  poorly water-soluble drugs,  prolong the half-life  of  drug of  drug
systemic circulation by reducing immunogenicity,  release drug at a sustained rate or
in  an  environmentally  responsive  manner  and  thus  lowers  the  frequency  of
administration.  Deliver drugs in a target manner to minimize systemic side effects
and delivers two or more drugs simultaneously for combination therapy to generate a
synergic effect and suppress drug resistance.
        As a result, a few pioneering nanoparticle-based therapeutic products have been
introduced  into  the  pharmaceutical  market  and  numerous  ensuing  products  are
currently under clinical testing or are entering the pipeline. 
Dept. Pharmaceutics.K.M.College Of Pharmacy Madurai
Introduction
1.7.  NANOPARTICLE  –  BASED  THERAPEUTIC  APPROVED  FOR
CLINICAL USE:
       In the past two decades, there has been a progressive increase in the number
of  commercially  available  nanoparticle-based  therapeutic  products.  A global
survey conducted by the European science and technology observation in 2006
showed that more than 150 companies are developing nanoscale therapeutics
 So far, 24 nanotechnology-based therapeutic products have been approved for
clinical  use,  with  total  sales  exceeding  $5.4  billion.  Among  these  products,
liposomal  drugs  and  polymer-drug  conjugates  are  two  dominant  classes,
accounting for more than 80% of the total amount. 
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Table 2.    MARKETED AVAILABLE NANOMEDICINES
Composition Trade
name
Company Indication Administratio
n 
      Liposomal platforms
Liposomal
amphotricin B
Abelcet Enzon Fungal
infection 
i.v
Liposomal IRIV Epaxal Berna
biotech
Hepatitis B i.m
Micellular
estradiol
Estrasorb Novavax Menopausal
therapy 
Topical 
Liposomal
morphine
Depodur Skye pharma Post  surgical
analgesic 
Epidural 
     Polymeric platforms
   PEG-anti-
VEGF aptamer
Macugen OSIpharma Age-related
macular
degeneration
i.m
PEG-GCSF Neulasta Amgen Neutropenia
associated with
cancer
chemotherapy 
s.c
PEG-L-
asparaginase
Oncaspar Enzon Acute
lymphoblastic
leukemia
i.v , i.m
Poly(allylamine
hydrochloride)
Renagal Genzyme End  –  stage
renal disease
Oral 
      Other platforms
Albumin  –bound
paclitaxel
Abraxane Astrazeneca Metastatic
breast cancer
i.v
Nano- crystalline
aprepitant
Emend Elan Anti – emetic Oral
      
 Table 3.ONGOING CLINICAL TRIALS IN NANOMEDICINES
                       
Composition Trade name Company Indication Administration Status 
        Liposomal platforms 
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Liposomal
annamycin
L- annamycin Callisto Acute  lympocytic
leukemia
i.v Phase I
Liposomal
doxorubicin
Sarcodoxome Gp – pharm Soft tissue sarcoma i.v Phase
I /II
Liposomal
lurtotecan
OSI-211 OSI pharma Ovarian cancer i.v Phase II
Liposomal
vincristine
Onco TCS Enzon Non  –  Hodgkin
lymphoma
i.v Phase
II /III
         Polymeric platforms
PEG-uricase Puricase Phoenix Hyperuricemia i.v Phase
III
Polycyclodextrin
camptothecin 
IT – 101 Insert therapeutic Metastatic  solid
tumors
i.v Phase I
Polyglutamate
paclitaxel
Xyotax Cell therapeutic Ovarian cancer i.v Phase
III
PEG-nalioxol NKTR-118 Nectar Opiod-induced
constipation
Oral Phase I
        Other platforms
Nanoemulsion-
based therapy
MB-001 Nanobio Herpes labialis Topical Phase II
Nanoemulsion-
based therapy
NB-002 Nanobio Onchomycosis Topical Phase
I/II
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Table 4.  PRECLINICAL NANOMEDICINES
 Composition Therapeutic Indication 
      Polymeric micells 
Pluronic block copolymers Doxorubicin Various cancers 
Polymer-lipid  hybrid
nanoprticles 
Doxorubicin Solid tumors 
Polymersomes Hemoglobin Oxygen carrier
Poly(vinyl  alcohol)  polymeric
micells
PVA  polymer  antitumor
activity
Neuroblastoma,
melanoma 
       Dendrimers
Folic  acid  –PAMAM
dendrimers
Methotrexate Epithelial cancer
 Polypropylenemine 
      Albumin-based nanoparticles 
Albumin-bound nanoparticles doxorubicin , methotrexate various cancers
     Polysaccharide-based nanoparticles
glycol chitosan nanoparticles doxorubicin solid tumors
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     1.8. NANOMEDICINE MECHANISM 6
            When a nanomaterial enters the human body, it immediately binds to various
proteins  and  amino  acids.  The  molecules  with  which  the  particles  will  attach
themselves to determine where it will.
            This binding process also affects the behaviour of the particle within the body.
Amino  acids  and  proteins  that  coat  nanoparticles  change  their  shape  and  surface
properties,  potentially increasing or reducing characteristics such as  toxicity,  or in
medical applications, the ability of particles to deliver drugs to target cells.
            To create the new method, the team used a variety of chemicals to probe the
surface of various nanoparticles, using techniques already developed by Xia. The size
of a nanoparticle and its surface characteristics determine the types of materials with
which it will link. Once the size and surface characteristics are known, researchers
can create "fingerprints" that identify the ways in which a given particle will interact
with biological molecules. These fingerprints allow to predict how the nanoparticles
might behave once you're inside the body.
            This information will allow us to predict where a particular nanomaterial will,
the human body, and whether or not it will be taken by certain cells, this in turn will
give us a better idea that nanoparticles may be useful for drug delivery and which can
be dangerous to humans or the environment.
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1.9. CLASSIFICATION OF NANOPARTICLES 7,8
A)  IN ONE DIMENSION (Thin surface coating)
      One-dimensional systems, such as thin films or manufactured surface.
B)IN TWO DIMENSIONS 
a) CARBON NANOTUBES
Carbon nanotubes are a new form of carbon molecule. Wound in a network of
carbon atoms, these hollow cylinders can have diameters as small as 0.7nm and reach
several millimeters in length. Each end can be opened or closed by a fullerene half-
molecule. These nanotubes can have a single layer (like a straw) or several layers (like
a poster rolled in a tube) of coxial cylinders of increasing.
C) IN THREE DIMENSION 
a)FULLERENES (Carbon 60)
Fullerenes are spherical cages containing from 28 to more than 100 carbon
atoms  (see  schematic  representation  opposite  fullerenes  are  a  class  of  materials
displaying physical properties.
They can be subjected to extreme pressures and regain their original shape
when the pressure is released. These molecules do not combine with each other, thus
giving them major potential for application as lubricants.
b)DENDRIMERS
Dendrimers  represent  a  new  class  of  controlled-structure  polymers  with
nanomeric  dimensions.  They  are  considered  to  be  basic  elements  for  large-scale
synthesis of organic and inorganic nanostructure with dimension of 1 to 100nm then
displaying unique properties .
Compatible with organic structure such as DNA, they can also be fabricated to
interact  with  metallic nano-crystals  and nano-tubes or to possess an encapsulation
capacity.
c) QUANTUM DOTS
It  represents  a  special  form  of  spherical  nanocrystals  from 1  to  10nm in
diameter.  They have been developed in the form of  semiconductors,  insulators,
metals, magnetic materials or metallic oxides.
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1.10. PRODUCTION PROCESS OF NANOPARTICLES7
                    The nanoparticles are prepared for following techniques,
1) Dispertion - based process 
2) Precipitation – based process
3) Interfacil polymerization
4) Nanoparticles formation by desolvation of macromolecules or coacervation
5) Solvent evapration
6) Solvent deposition
1)  DIRPERSION – BASED PROCESS
a) WET MILLING
      Wet milling is an attrition-based process in which the drug is dispersed first in
an aqueous-based surfactant solution. The resulting suspension is subjected to wet
milling using a pearl mill in the presence if milling media.
b)  HIGH – PRESSURE HOMOGENIZATION
High-pressure homogenization is based on the principle of cavitations (i.e., the
formation, growth, and implosive collapse of vapor bubbles in a  liquid.  In  this
process,  a  drug  pre-suspension  (containing  drug  in  the  micrometer  range)  is
prepared by subjecting the drug to air jet milling in the presence of an aqueous
surfactant  solution.  The  main  advantage  of  high-pressure  homogenization  is
suitable  for  both  large  and  laboratory  scale  production,  because  high-pressure
homogenizers are available in various sizes. In addition, homogenization creates
negligible  nanoparticle  contamination,  which  is  one  of  the  most  important
objectives  of  a  nanoparticle  production.  A limitation of  this process  is  that  the
pressure used is so high that in some case, the crystal structure changed.
c) EMULSIFICATION TECHNOLOGY
Emulsification also can be used to prepare nanoparticle suspensions. In this
method, the drug solution in an organic solvent is dispersed in the aqueous phase
containing surfactant. This step is followed by the evaporation of organic solvent
under reduced pressure, which results in the preparation of drug particles to form a
nanoparticle suspension which is stabilized by the added surfactant.  The use of
micro emulsion as templates for producing drug nanosuspension .  
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d) PRECIPITATION – BASED PROCESS
a)  SPRAY FREEZING INTO LIQUID (SFL)
In this process , developed at the university of Texas at Austin (Austin, TX)
and  commercialized  by Dow chemical  company (  midland,  MI)  ,  an  aqueous,
organic,  or  aqueous  co-solvent  solution,  aqueous-organic  emulsion  ,  or  drug
suspension is atomized into a cryogenic liquid such as liquid nitrogen to produce
frozen  nanoparticles  which  are  subsequently  lyophilized  to  obtain  free  flowing
powder. 
b)   EVAPPORATIVE PRECIPITATION INTO AQUEOUS SOLUTION (EPAS)
The EPAS process also was developed by the University of Texas at Austin
and commercialized by Dow chemical company. In this process, the drug solution
on boiling liquid organic solvent is heated under pressure to a temperature above
the solvent normal boiling point and then atomized into a heated aqueous solution
containing stabilizing surfactant.
c) RAPID EXPANSION FROM A LIQUID – GAS SOLUTION (RESS)
In an RESS process, a solution or dispersion of phospholipids or other suitable
surfactant in the supercritical  fluid is formed. Then, rapid nucleation of drug is
induced in the supercritical fluid containing surfactant. This process allows rapid,
intimate  contact  of  the  drug  dissolved  in  supercritical  fluid  and  the  surfactant
which inhibits the growth of the newly formed particles.
d)   PRECIPITATION  WITH A COMPRESSED  FLUID ANTI  –  SOLVENT
(PCA)
In the PCA process (patented by RTP pharmaceuticals and licensed to skye
pharma PLC (London, UK), supercritical  carbon dioxide is  mixed with organic
solvent containing drug compounds. The solvent expands into supercritical carbon
dioxide, thus increasing the concentration of the solute in the solution, making it
supersaturated, and causing the solute to precipitate or crystallize out of solution.
e)  INTERFACIAL POLYMERIZATION
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In interfacial polymerization process takes place at the interface between two
immiscible phases. The monomer and the lipophillic drug are dissolved in oil or in
benzyl  benzoate.  The organic phase  is  slowly added  through a small  tube  under
permanent stirring at PH 6 to the aqueous phase containing a surfactant.
f) NANOPARTICLES  FORMULATION  BY  DESOLATION  OF
MACROMOLECULES OR COACERVATION
Macromolecules in solution have an expanded swollen random structure. To
better the solvent is more diluted leads to more swelling of the molecule. Addition of
a de-solvating agent (non solvent), charge changes or PH changes reverse this process
and  result  in  the  de-salvation  of  the  macromolecules.  This  process  is  commonly
known as co-acervation, a new phase (coacervate phase) is formed . The coacervate
phase  when  treated  with  a  cross  linking  aldehyde  produce  nanoparticles  of  the
macromolecule.
g)  SOLVENT EVAPORATION
In this process, a polymer is dissolved together with a hydrophobic drug in a
volatile  and water  immiscible organic solvent.  The latter  is  dispersed in water  by
stirring and evaporated under reduced pressure. The polymer precipitates in the form
of  microspheres  containing  the  drug  finely  dispersed  in  the  polymer  matrix.
Nanoparticles can be formed of the organic mixture is emulsified to form submicron
size droplets, using a dispersing agent and high energy homogenization. 
h)  SOLVENT DEPOSITION
In this process polymers as well as phospholipids are dissolved in acetone. A
solution of the drug in benzyl benzoate is than added to the organic phase, and this
mixture  is  subsequently  poured  into  water  containing  0.5%  polymer  188  under
moderate stirring. Nanocapsules with an oily core are formed instantaneously. This
suspension then has to be concentrate to about 10ml final volume by evaporation of
acetone and partial removal of water under reduced pressure.
 
 1.11.   APPLICATION OF NANOPARTICLES7
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 Nano medicines: nanodrug , medical devices , tissue engineering etc.,
 Ceramic  based  nanoparticles  for  entrapping  therapeutic  agent  for
photodynamic  therapy,  in  this  method  of  the  photosensitive  drug/dye  is
entrapped with ceramic carrier . These ceramic nanoparticles are widely used
for skin and therapeutic purpose.
 The thermo sensitive nanoparticle may be used for  selective release of  the
content after specific localization like photodynamic therapy.
 Materials: nanoparticles, carbon nanotubes, biopolymers, paints, coating .
                Table 5. Application of nanoparticles
S.NO APPLICATION            MATERIALS  PURPOSE
1 Intracellular
targeting
 Poly  (alkylcyanocrynate)  poly
ester,  nanoparticle  with  anti-
neoplastic or antiviral agent
Target reticulo-endothelial system
for intracellular infection
2 Vaccine adjuvant Poly(methylmethacrylate)
nanoparticles  with  vaccines  oral
and intramuscular immunization
Enhances  immune  response  ,
alternate acceptable adjuvant
3 DNA delivery DNA  –  gelatin  nanoparticles,
DNA-chitosan  nanoparticles,
PDNA-poly  (DL-lactide-co-
glycolite ) nanoparticle
Enhanced  delivery  and
significantly  higher  expression
levels
4 Cancer therapy Poly(alkylcyanoacrylate)
nanoparticles  with  anticancer
agents
Targeting  reduced  toxicity,
enhanced  uptake  of  antitumor
agents , improved in-vitro and in-
vivo stability
5 Per  oral
absorption
Poly (methacrylate) nanoparticles
with  proteins  and  therapeutic
agents
Enhanced  bioavailability
protection from G.I.T
 1.12. DIURETICS 9,10
Definition: Diuretic agents are drugs that increase renal excretion of water
and solutes (mainly sodium salt)
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Mechanism of diuretics:
 Diuretic  act  by  inhibiting  sodium  reabsorption  in  the  renal  tubules,
thereby increasing urinary sodium , and consequently , water loss,
  Agents differ with respect to the specific tubular ion transport system
they inhibit,
 Site of action within the nepron
 Natriuretic efficacy
 Pharmacological effects
 Clinical indications
 Site of action located on the luminal surface of the tubule
 Extensively bound to serum albumin
 Transported into the proximal tubule lumen by active secretion
 Organic  acid  secretory  pathway  :  thiazides  ,  loop  diuretics  ,
acetazolamide
 Organic base secretory pathway : potassium-sparing diuretics
 Exception  :  spiranolactone  and  eplerenone  enter  renal  tubules  from
plasma
Major purpose of diuretic therapy are to decrease fluid volume of the body,
and to adjust the water and electrolyte balance .
Diuretics are often used in the management of pathological conditions such as
edema (e.g. In congestive heart failure and certain renal disease) and hypertension .
Diuretics  may be  used  in  surgery  to  reduce  blood  pressure  and  swelling,
(mannitol, an osmotic diuretic may be used to reduce swelling in the brain for some
neurosurgical procedure)
Table 6.  Types of diuretics :
Type Example Site of action Mechanism
Carbonic  anhydrase Acetazolamide Proximal Inhibition  of
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inhibitors tubule CA
Osmotic Mannitol Loop of Henle
,proximaltubu
le
Osmatic
action
Loop diuretics Furosemide Loop of Henle Inhibition  of
Na+-k+-2Cl-
Symport
Thiazide Hydrochlorothiazide Distal
convoluted
tubule
Inhibition  of
Na+-Cl-
symport
Potassium-Sparing
diuretics  
1) Na+  channel
inhibitors
2) Aldosterone
spiranolactone
Triamterene,
Amiloride
Cortical
collecting
tubule
Cortical
collecting
tubule
Inhibition  of
Na+ channel
Inhibition  of
Na+ channel
Adverse effects of diuretic drugs:
Hypotension  and  orthostasis,  Volume  depletion,  Electrolyte  disorder,
Hypokalemia,Hypomagnesemia,  Hyponatremia,  Hypocalcemia  (loopdiuretics),
Hypocalcemia  (thiazides),  Hyperuricemia,  Hyperglycemia,  glucose  intolerance,
Dyslipidemia, Photosensitivity and skin reaction, Oxotoxicity, Interstitial nephitis.
Dept. Pharmaceutics.K.M.College Of Pharmacy Madurai
Literature review
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A.umar  faruksha11et  al.,(2010)  formulated  nanoparticle  for  Pioglitazone
Hydrochloride having low solubility and high permeability were prepared by solvent
evaporation  displacement  method.  The dissolution  profile  of  all  formulations  was
fitted to zero order, Higuchi and Korsemayer Peppas models to ascertain the kinetic
modeling of drug release. The prepared formulations were further evaluated for drug
content,  drug-  excipient  interactions,  surface  morphology  by  SEM,  differential
scaning  calorimetry  (DSC),  Zetapotential.  All  formulations  were  found  to
significantly  influence  the  particle  size  and  entrapment  efficacy.  the  in-vitro drug
release  profile  showed  that  the  suitability  of  chitosan  loaded  nanoparticles  in
sustaining Pioglitazone release for prolonged time.
         Heati H12  et al.,(1997) prepared the solid lipid nanoparticles (SLNs) using
Trilaurine (TL) as the SLN core and phospholipid ( PL ) as coating . The stability of
SLNs formulations  containing AZT-P was  studied  at  different  temperatures.  Drug
retention  and  mean  particle  diameter  of  SLNs  were  determined  after  autoclaving
during  temperature  stability  testing  and  after  lyophilization(with  or  without
cryoprotective sugars) and reconstitution. There were no significant changes in the
mean diameter and the zeta potential of SLNs after autoclaving (121o C for 20 mins).
SLNs containing AZT-P can be  autoclaved,  lyophilized and  reconstitution without
significant changes in SLN diameter.
       Jin – ki kim 13 et al.,(2010) developed Lipid nanoparticles of Itraconazole ( ITZ )
to proved the controlled release of ITZ as well as improve the solubility of ITZ by
high-pressure homogenization method.  The particle  size and poly dispersity index
(PI) of lipid nanoparticles were below 280nm and 0.2nm respectively. Zeta potential
and incorporation efficiencies of lipid nanoparticles were around – 30m V and above
80%, respectively.  SEM, DSC, and PXRD revealed that ITZ in lipid nanoparticles
exist in an amorphous state. Release rates were increased as the amount of liquid lipid
in  lipid  core  increased.  The  release  of  ITZ  from  lipid  nanoparticles  could  be
controlled by modulation of the amount of liquid lipid in lipid core. 
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          C.X. Song 14 et al.,(1997) formulated various drug – loaded (lactic-co-glycolic
acid)  (PLGA)  nanoparticles  (NP)  using  an  emulsification  /  solvent  evaporation
technique. Different emulsion systems were employed according to the solubility of
individual  drugs.  Bovine  serum  albumin  was  model  protein  during  loaded  on
nanoparticles 10% to 30%. Typical particle size rearranged from 60-200nm with 80%
of the particles in the range of 70-165 nm. The invitro release rate for albumin was
dependent upon the molecular weight (MW) of PLGA. Nanoparticles with smaller
mean size (100nm vs. 266nm) and lower drug loading (13.1% vs. 20.7%) resulted in
higher  arterial  uptakes  compared  to  nanoparticles  of  larger  size  and  higher  drug
loading.  A wide  variety  of  water  soluble  and  insoluble  bioactive  agents  can  be
incorporated  into  PLGA nanoparticles  with  a  high  efficiency and  adjustable  drug
loading.
        Einat cohen-sela 15 et al.,(1994) described about double system with a partially
water-soluble organic solvent, could result in better encapsulation yield of hydrophilic
molecules in nano-sized NP, and the utilization of both biocompatible surfactant and
solvents. As a model drug they used Alendronate, a hydrophilic low molecule weight
bio phophosnate. The NP preparation technique of double emulsion solvent diffusion
(DES-D) method resulted in improved formulation characteristics including smaller
size,  lower  size  distribution,  higher  encapsulation  yield  and  more  biocompatible
ingredients  in  comparison to  classical  methods.  The utilization of  partially  water-
miscible organic solvent (ethyl acetate) enabled rapid diffusion through the aqueous
phases forming smaller NP.
          D.Dhachinamoorthi16 et  al.,(2001) prepared Acyclovir  loaded chotosan
nanoparticles were by ionic gelatin of chitosan with sodium tripolyphosphate (0.25%)
prepared in the presence of Tween 80 ( 0.5% ) as a re-suspending agent to prevent
aggregation,  at  ambient  temperature while  stirring.  The DSC thermogram was  no
chemical  interaction  between  acyclovir  and  chitosan.  The  mean  particle  size,
morphological  characteristic  and  surface  property  of  the  nanoparticle  appear  to
depend on concentration of Acyclovir, loaded chitosan nanoparticles.  The effective
use of acyclovir loaded chitosan nanoparticles as a controlled release preparation for
treatment of ocular viral infections.
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        Xinyi Gu 17 et al.,(2005)  studied that many drugs, due to their hydrophilicity,
have poor loading in nanoparticles, which has been limited drug delivery.  Charge-
charge  interaction  may  be  effective  for  improving  loading  where  charges  in
nanoparticles attract oppositely charged drug molecules. A new strategy, incorporation
of  charged  hydrophobic  excipients  into  nanoparticles  followed  by  drug  loading
incubation of nanoparticles in the presence of drug solution, may effectively increase
drug loading.  Ion pairing between alkyl sulfates and doxHCL yielded hydrophobic
complexes based on solubility and partition coefficient determination and indicated
favorable incorporation into hydrophobic nanoparticle cores. However, encapsulation
into nanoparticle failed due to poor complex solubility in organic solvents and no
significant improvement in drug loading after incorporation.       
                     
        Kharia Ankit Anand 18 et al.,(2008) described in recent years scientific and
technological advancement have been made in the rate controlled oral drug delivery
system  by  overcoming  advertise,  such  as  short  gastric  residence  time.  Various
polymers  have  been  used  in  the  formulation  of  stomach  specific  mucoadhesive
nanoparticles for drug delivery to increase therapeutic benefit, while minimizing side
effects. Discussed about concept of gastric emptying, absorption window, potential
drug candidates, technological development evaluation and applications for stomach-
specific mucoadhesive nanoparticles .
       Jundong Dai 19 et al.,(2004) prepared the Cyclosporine pH sensitive NP, using
poly  (methacrylic  acid  and  methacrylate)  copolymer  by  quasi-emulsion  solvent
diffusion  technique  and  evaluated  the  characterization,  dispersion  state  of
cyclosporine at the surface or inside the polymer matrices of the NP,  s invitro release
the PH-sensitive NP,s can be designed as new Cyclosporine carriers with improved
oral bioavailability of Cyclosporine. 
       Devarajan  PV20 et  al.,(2007) formulated  the  Gliclazide  Loaded  Eudragit
nanoparticles  (Eudragit  L 100 and  Eudragit  RS)  as  a  sustained  release  carrier  by
controlled precipitation method for Eudragit L 100 nanopatricles, solvent evaporation
method for Eudrgit RS nanoparticles. The influence of various formulations factors
(stirring  speed,  drug  polymer  ratio,  homogenization  &  addition  of  surfactant)  on
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particles  size drug loading & encapsulation  efficiency.  Eudragit  nanoparticles  had
decreased  time,  enhanced bioavailability & sustained  activity.  Hence  the Eudragit
nanopaticles could reduce dose frequently,  decrease side effect  & improve patient
compliance.
       Andre .A. Onischuk 21  et al.,(2008) practiced the respiratory system provides
entry for drug nanoparticles to cure systemic disease. The modern devices that are
available on the market  of therapeutic Aerosol delivery systems have a number of
disadvantages.  There  remains  a  need  for  an  alternative  means  that  is  low  cost,
convenient, and capable of producing small-sized particles. On the other hand, one
-third  of  the  modern  drugs  are  poorly  water  soluble.  Many  currently  available
injectable  formulations  of  such  drugs  can  cause  side  effects  that  originate  from
deterginate  and  other  agents  used  for  their  solubilization.  The  aerosol  lung
administration  may  be  a  good  way  for  delivery  of  the  water-insoluble  drugs.
Indomethacin nanoaerosol  formaed and its  anti-inflammatory effect  of the outbred
male mice was examined. The aerosol lung administration experiments were carried
out  in  the  whole-body  exposure  champer.  The  anti-inflammatory  action  and
pulmonary  effects  caused  by  the  inhalation  of  Indomethacin  nanoparticles  more
effective than peroral  treatment.  The aerosol route required a therapeutic  dose six
orders of magnitude less than that for peroral administration.
       F. De Jaeghere 22  et al.,(2009) incorporated the poorly water soluble HIV – 1
protease inhibitors into PH – sensitive nanoparticles & macroparticles made of poly
(methcrylic acid – co – ethylcrylate) copolymer Eudragit  L100-55 .  Nanoparticles
were  characterized  in  terms  of  morphology,  size  –  distribution,  drug  loading,
production yield,  invitro & invivo  release studies in beagle dogs.  potential of PH-
sensitive particles for the oral delivery of HIV – 1 protease inhibitors with low water
solubility.
       S. Ramesh 23 et al.,(2010) prepared the nanoparticles by using sepia (cuttle fish
ink) Ciprofloxacin Hcl was used as a model drug . The prepared formulations were
subjected to different invitro analysis such as content analysis, particle size analysis,
Zeta potential analysis,  invitro drug release and stability studies. The particle size is
about 500nm, the drug content is in the range of drug release was about 85%. CN3
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formulations were found to be the best formulation with higher cumulative percentage
of drug release.
        Partha Saha 24et al.,(2011) developed Ampicillin Trihydrate-loaded chitosan
nanoparticles  by modified  ionic  gelation  method and  evaluate  their  Antimicrobial
activity.  Parameters such as zeta potential, polydispersity, particle size, entrapment
efficiency and invitro drug release of the nanoparticles were assessed for optimization.
Concentration of 0.35%w/v of chitosan and 0.40%w/v sodium tripolyphosphate (TPP)
and  a  sonication  time  of  20  min  constituted  the  optimum  conditions  for  the
preparation of  the nanoparticles  .  The  invitro release data  showed an initial  burst
followed  by  slow  sustained  drug  release.  Polymer  and  cross  linking  agent
concentration and sonication time are rate-limiting factors for the development of the
optimized formulation. The chitosan nanoparticles  developed would be capable of
sustained delivery of Ampicillin Trihydrete.
.
       Mohamed Vaseem25et al.,(2005) synthesized Zno nanoparticles by either sol-gel
method  or  hydrothermal  method.  Synthesis  of  Zno  nanoparticles  in  the  solution
requires a well defined shape of Zno nanoparticles . And reported room-temperature,
organometallic synthesis of Zno nanopaticles of controlled shape and size an solution.
The decomposition of Organomatallic precursor to the oxidized material in air. This
preparation  was  characterized  by X-ray diffraction  (XRD & TEM  conformed as
agglomerated Zno nanoparticle with a zincite structure having lack of defined shape
and size .
       Eliao Leo26et al.,(2009) prepared the PLA nanoparticles containing a lipo-philic
drug  in  water-soluble  form (  AD6 )  & in  water  insoluble  form (  AD6-acid  )  by
nanoprecipitation method the nanoprticles were subjected to evaluation such as drug
content, mean particles size, invitro  release.  They changing the pH of the aqueous
phase, the drug content dramatically increased .
       Kathleen Dillen27et al.,(2008) developed the PLGA nanoparticles incorporating
Ciprofloxacin  HCL  by  W/O/W  emulsification  solvent  evaporation  method.  The
effects of different preparation factors of the nanoparticles physiochemical properties
like particle size, zeta potential, drug loading efficiency and drug release and they
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concluded  that  the  homogenization  decrease  the  particle  size  and  release  rate  of
ciprofloxacin, but increased entrapment efficiency, addition of boric acid to the inner
water  phase,  increase drug release rates  but  only after  6.5  hrs.  Also the  effect  of
gamma radiation on the  particle  size and drug release was  evaluated.  Differential
scanning colorimetry & x-ray diffraction analysis were performed.
       Hannele  Eerikanen28  et  al.,(2010) described  polymeric  drug  containing
nanoparticle were prepared using a novel aerosol flow reactor method. The polymeric
drug containing nanoparticle prepared consist of a poorly water soluble corticosteroid
Beclomethasone Bipropionate and polymeric materials Eudragit E 100 or Eudragit L
100.  The  novel  method  used  in  this  preparation  allows  synthesis  of  nanoparticle
directly as dry powder. The nanoparticle contain various ratio of drug and polymer &
use of any additional stabilization materials is avoided. All the nanoparticle produced,
regardless  of  particle  composition,  has  geometric  number  mean  diameter  of
approximately 90nm and  were  spherical  showing  smooth  surfaces.  The  drug  was
more currently polymeric matrix dispersed in the amorphous polymeric matrix of the
nanoparticle and drug crystallization was not observed, when the grass transsitition
temperature of the polymer .
     Rubiana29 et al.,(2012) prepared spherical nanoparticulate drug carriers made of
Poly  (d,1-lactide-co-glycolide)   acid  with  controlled  size   Praziquantel  is  a
hydrophobic molecule, was entrapped into the nanoparticles with theoretical loading
varying from 10 to 30% (w/w).  The effects of some process variables on the size
distribution of nanoparticles prepared by emulsion-solvent evaporation method. The
results show that sonication time, PLGA and drug amounts, PVA concentration, radio
between aqueous and organic phases, and the method of solvent evaporation have a
significant influence on size distribution of the nanoparticles. 
       Mainardes  Rubiana  Mara30 et al.,(2010) developed PLA and PLA/PEG blend
nanoparticles  containing  Zidovudine  and  their  uptake  by  polymorphonuclear
leucocytes were studied in invitro release. The cells were isolated from rat peritoneal
exudates and their activation by nanoparticles was measured by luminol-dependent
chemiluminescence and microscopical  analysis.  The phagocytosis depended on the
PEG and its radio in the blend, the results showed that the PLA nanoparticles were
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more efficiently phagocytosed than PLA/PEG blends. The blend with the highest PEG
proportion did not prevent phagocytosis, indicating that the steric effect of PEG was
concentration dependent.
       Esko I . Kavappinen31 et al.,(2012) focused on the development of nanoparticle
systems for  Anti-microbial  drug to  kill  or  inhibit  the  growth of  microbes  such as
bacteria, fungi  & viruses. Even though the therapeutic efficiency of these drugs has
been well established inefficient delivery could result in inadequate therapeutic index
and local and systemic side effect include cutaneous irritation, peeling, and scaling &
gut flora reduction. Nano structured bio-material in nanoparticle in particular, have
unique physicochemical  properties  such as  ultra  small  and controllable size,  large
surface  area  to  mass  ratio  ,  high  reactivity  &  functionalizable  structure.  These
properties can be applied to facilliate the administration in traditional anti-microbial
therapeutics. In recent years , encapsulated of Anti-microbial drugs in nanoparticle
systems  has  emerged  as  an  innovative  and  promising  alternative  that  enhances
therapeutic effectiviness and minimizes undesirable side effects of the drugs . 
       Yadav SC32 et al.,(2010) investigated on Biodegratable polymeric nanoparticles
based drug delivery systems nanoparticulate drug delivery system seem to be a viable
and promising strategy for the biopharmaceutical  industry.  It  can increase the bio-
availability,  stability  and  permeability  of  many potent  drugs  which  are  otherwise
difficult to deliver orally. Nanoparticle drug delivery systems will also reduce the drug
dosage  frequently  and  will  increase  the  patient  compliance.  In  near  future
nanoparticulate  drug delivery systems can be used for  exploiting many biological
drugs which have been poorly water solubility, permeability and less bio-availability
nanoparticles  provide  ingenious  treatment  by  enabling  targeted  delivery  and
controlled release.
       Roberta cavalliTrotta33 et al.,(1997) prepared  (SLN) from three oil in water
micro emulsions , where internal phase was constituted of different lipid matrics. The
dispersion media were two aqueous solutions of trehalose and pluronic F68 at 2%
besides  distilled  water.  SLN  were  sterilized  by  autoclaving,  were  stable  during
sterilization  and  maintained  a  spherical  shape  and  narrow  size  distribution  as
confirmed by TEM analysis . SLN dispersion in water did not present nanoparticles
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large than after at 4o C for 1 year they were freeze dried sterilization to obtain dry
products .   
       Morteza Azhdar34 et al.,(2010) prepared Azithromycin nanoparticle by modified
solvent  diffusion  method.  The  anti-bacterial  activities  of  prepared  nanoparticle  in
comparision with Azithromycin solution were assayed against indicator bacteria of
Escharichia coli (PTCC-1330), Haemophilus influenza (PTCC-1623) & streptococcus
pneumonia (PTCC-1240) using agar well diffusion. Inhibition zone diameters (IZD)
of  nano-formulation  were  compared  to  the  corresponding  untreated  AZI.  Mean
inhibitory concentration (MIC) were also determined using serial dilution method in
nutrient broth medium. The enhanced anti-bacterial efficacy was more dominant in
the gram positive species. The MIC values of nanoparticles against the tested bacteria
were reduced 8 times in comparison to those of untreated AZI. An improved potency
of AZI nanoparticles which could be attributed to the modified surface characteristic
as well as increased drug absorption and uptake.
       Jahangiri  L et al.,(2013) developed importance and increasing application
nanoparticles  and  their  toxicity,  the  identification  effect  of  nanoparticles  on
physiological  systems  are  essential.  Some studies  show magnesium has  analgesic
effect in some pain models but this evaluation was not carried on nano-Magnesium
oxide (MgO) thus, present study was designed evaluation effect of MgO nanoparticles
alone and in combination with Ketamine on pain and inflammation model in mice. 
   
       Vivek kumar gupta36 et al.,(2009) formulated Nanoparticle of 5-Flurouracil
using  chitosan  polymer  and  pregelated  using  alginate  by  ionotropic  pregelation
method.  Calcium chloride was also included in  the formulation for  pregelation of
sodium alginate  prepared  1% acetic  acid  solution  of  chitosan  and  pre  gelation  of
sodium  alginate  suspension  further  cross-linked  with  gluteraldehyde.  Different
formulation of nanoparticles were prepared using different concentration of chitosan,
stirring speed, time of rotation and polymer to drug ratio in the nanoparticles. The
average  particle  size  ranged  between  246nm to  620nm.  Drug  entrapment  ranged
between  71.9%-89.90%.  The  drug  loaded  nanoparticle  of  5-flurouracil  showed
optimum particle size and maximum drug entrapment with drug polymer ratio 05:75,
cross-linking agents, stirring speed 800rpm and stirring time 90min.
Dept. pharmaceutics. K.M College Of Pharmacy, Madurai
Page 30
Literature review
       Peng Guo37 et al.,(2005)  prepared hydrophobic drug nanopaticle by nanoporous
membrane  extrusion.  NME  is  based  on  the  induced  precipitation  of  drug-loaded
nanopaticle  at  the  exists  of  nanopores.  These  common  hydrophobic  drug  models
(silymarin  ,  β-carotene)  were  tested.  Themmorphology,  crystallinity,  dissolution
profile  of  resulting  nanoparticle.  Using  NME,  the  successfully  prepared  rather
uniform drug nanoparticle. These nanoparticle were amorphous and show improved
dissolution profile  compared  with untreated  drug powder.  NME could be used as
general method to produce nanopaticle drug.  
 Rubina M . Marnardes38 et al.,(2010) designed nanoparticles for Praziquentel using
poly (D , L-lactide-co-glycolide) (PLGA) as a carrier. The effects of some process
variables  on  the  size  distribution  of  nanoparticles  prepared  by  emulsion  solvent
evaporation  method.  The  results  showed  that  sonication  time,  PLGA and  drug
amounts,  PVA concentration,  ratio  between  aqueous  and  organic  phases  and  the
method of solvent evaporation have a significant influence on size distribution of the
nanoparticles.
       Swarnali Das39 et al.,(2011)  prepared Am-B loaded Eudragit nanoparticles by A
solvent displacement technique . These NPs had a mean size range of 150-290m and a
zeta potential  of  +19-28 mV. Even  after  6  months  of  stability study,  results  were
unchanged the good potential for ocular application. In vitro release studies revealed
that a maximum amount of drug was released within 24 hours (60%). The  microbial
assay showed that the anti fungal activity of drug-loaded NPs was equal to or slightly
lower than that of free-AmB solution . In vivo experiments showed that, following
topical installing of nanosuspension to a rabbit eye there was no irritation. Eudragit
RS 100 nanosuspension may represent an efficacious vehicle to deliver the drug into
drug into the eye.   
       Adlni jino nesalin40 et al.,(2009) prepared Flutamide nanoparticles by ionic
gelation technique. Nanoparticles of different core:  coat  ratio were formulated and
analyzed for the total drug content, loading efficiency, particle size and in vitro drug
release studies it was observed that nanoparticles prepared with chitosan in the core:
coat gives better sustained release for about 12 hrs compared to other formulations.
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       J. Vandervoot 41 et al.,(2002) prepared nanoparticles by W/O/W emulsification
solvent evaporation method. Poly (vinyl alcohol) is used as stabilizer of the emulsion.
The influence of the concentration of PVA and the polymers tested on particle size
and zeta potential value was evaluated before and after freeze-drying of the prepared
particles. Nanoparticles were obtained with the formulations, however, increased the
size of the particles over 1 m. Two exceptions are Poloxamer and Carbopol, which
can  be  considered  as  valuable  alternatives  to  PVA.  Zeta  potential  values  were
measured when Poloxamar and Carbopol were employed. The use of gelatin type A
made it possible it achieve values.
         T. Vetrichelvan42 et al.,(2011) prepared Alginate nanoparticles by in situ nano
emulsion polymer cross  linking approach.  The nano particles  were prepared using
different ratios of alginates and Abacavir sulfate in the ratios of (1:1, 1:2 and 1:3)  The
result of ratio 1:3 showed a good encapsulation efficiency of 98.71%. Abacavir sulfate
nanoparticles  was  confirmed  by  FT-IR,  DSC  and  quantitated  by  uv  prepared
nanoparticle   appeared  spherical  with  a dense drug core in transmission electron
microscopy  studies . Hydro dynamic diameter of nanoparticles was 63 +/- 0.235 nm,
with a Gaussian distribution and the zeta potential-0.6. The nanoparticle technique
developed can be a good choice for the development of sustained antiretroviral drug
carrier.
          
             N.Jawahar43 et  al.,(2009)  prepared  Poly (D,L-Lactide-co-Glycolide)
(PLGA)  nanoparticles  by  nanoprecipitation  method  using  tribloere  polymeric
stabilizer (Pluronic RF-68). The particles were characterized for drug content, particle
size and particle morphology by Transmission electron microscope (TEM). In vitro
studies were determined by the bulk equilibrium reverse dialysis bag technique. The
particle  size  of  the  prepared  nanoparticles  ranged  from  200nm  to  340nm.
nanoparticles of Ramipril were obtained with high encapsulation efficiency (68-75%).
The drug release from the Ramipril  nanoparticles  was sustained in Batch (F3) for
more  than 24  hrs  with  72% drug  release.  The feasibility  of  formulating Ramipril
loaded  PLGA nanoparticles  can  be  used  to  improve  the  therapeutic  efficacy  of
Ramipril in the treatment of hypertensive disorder.
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            Atul Gaikwad44 et al.,(2010) described about Furosemide loaded Eudragit
RS100  nano  particles  prepared   by  nanoprecipitation  method.  The  shape  of
nanoparticles was found to be spherical by scanning electron microscopy study where
as  size ranging from 163nm to 378nm. FT-IR study confirmed that  there was no
interaction between drug and polymer.  Entrapment efficiency in the range of 14.95-
0.06  to  69.73-0.03  W/W.  Zeta  potential  of  formulation  supports  the  minimum
interaction  between  the  particles.  The  invitro  drug  release  study  revealed  that
sustained  release  of  some  formulation  last  up  to  24  hour.The  release  followed
Higuchi kinetics, which indicates diffusion controlled release pattern of drug.
S.Tamizhrasi45 et  al.,(2009) studied  the  preparation  and  evaluation  of  poly
Methacrylic acid nano particles containing Lamivudine in different drug to polymer
ratio  by  nanoprecipitation method. SEM indicates that nano particles have a discrete
spherical structure without aggregation. The average particle size was found to be 121
to 403nm. The drug content of the nanoparticles was increasing on the increasing
polymer concentration up to a particular concentration. FTIR studies indicate there
was no chemical interaction between drug and polymer and stability of drug. The
invitro release behavior from all the drug loaded batches was found to be zero order
and  provided  sustained  release  over  a  period  of  24  hours.   The  development
formulation  overcome and  alleviates  the  drawbacks  and  limitation  of  Lamivudine
sustained release formulations.
Sergio  A46 et  al.,(2005) studied  the  scale  up  technologies  for   Ibuprofen  loaded
nanoparticles by three manufacturing process salting out, emulsification diffusion and
nanoprepicitation to pilot scale by increasing 20 fold laboratory –batch  volume from
60ml to  1.5L using Eudragit  L100-55 as  polymer.  Influence of  the photodynamic
condition on the nanoparticles characteristics in the scale up process and concluded
that  nanoparticles were  reproduced well  at  both scales,  however included a slight
reduction in the size and drug loading of nanoparticles.
Arvind Gulbake 47et al.,(2012) described Chitosan nanoparticles (CH-NPs) bearing
Mesalazine  by ionotropic gelation method and encapsulated in Eudragit S 100 coated
pellets for site specific delivery to ulcerative colitis. The CH-NPs were characterized
for  size  and  structured  using  Malvern  zetasized  and  transmission  electron
spectroscopy (TEM). The average size of the un-coated CH-NPs was about 157.3±
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7.1 nm, with the zeta potential of 32.2±2.1nm, suitable for uptake through the colonic
mucosa due to their nanosize range and mucoadhesive properties. The invitro drug
release from developed formulations was investigated using a USP dissolution rate
paddle-type apparatus.  Different stimulated gastrointestinal  tract  fluids. The coated
formulation shows no release and un-coated CH-NPs showed 4.98±0.24%, of MSZ in
SGF (PH 1.2). The release of drug from coated nanoparticles was PH responsive. At
the end of MSZ was released 24 hrs 69.24 ± 3.4% , & 45.26 ± 2.4 % of MSZ was
released CH-NPs . The MSZ and pellets of CH-NPs and EC-CH-NPs bearing MSZ
were separately administrated orally at the dose of 50mg/kg body weight to albino
rats and evaluated for anti-ulcerogenic activity. Anti-ulcerogenic activity studies on
albino  rats  were  done  for  determining  the  effectiness  of  formulations  in  the
management of ulcerative colitis.
 Rakesh  kumar  sharma48 et  al.,(2013)   developed  Metformin  solid  lipid
nanoparticles  (M-SLN) and incorporate it in the transdermal patches. M-SLN was
evaluated for Particle size, Zeta potential, Patches were evaluated by Ex-vivo skin
permeation  studies.  M-SLN  was  prepared  by  solvent  diffusion  technique  using
propylene glycol (solvent), polymethacrylic acid (polymer) and Soya lecithin (lipid
base).  The particle size of M-SLN varied among the formulation due to variation in
the composition of formulations. Zeta potential of best formulation was found to be
+27mV. SEM   and TEM indicate discrete spherical structure without aggregation.
Drug content was found to be 1.45mg/patch.  Transdermal delivery of M-SLN is a
safe, painless and cost effective drug delivery system for diabetes patients.
 Waree Tiyaboochai 49 et al.,(2001) Studied that Chitosan nanoparticles have gained
more attention as drug delivery carriers because of their better stability, low toxicity,
simple and mild preparation method, and providing versatile routes of administration.
Their sub-micron size not only suitable for parenteral application, but also applicable
for  mucosal  routes  of  administration,  i.e.,  oral,  nasal,  and  ocular  mucosa,  which
arenon-invasive  route.  The  application  for  mucosal  delivery  also  facilitated  by
chitosan  absorption  enhancing  effect.  Furthermore,  chitosan  nanoparticles  also
showed to be a good adjuvant for vaccines. 
 Ravindra Kulkarni  50 et al.,(2010) developed and formulate the sustained release
Glipizide  loaded  nanoparticles  and  evaluate  it.  Emulsification-solvent  evaporation
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technique. The optimized nanoparticles formulation were studied for FT-IR, particle
size, zeta potential, encapsulation efficiency, XRD, in vitro release study and in vivo
evaluation  etc.  The  effects  of  dependent  variables  drug-polymer  ratio  (X1)  and
surfactant  concentration  (X2)  on  particle  size  and  encapsulation  efficiency  were
studied. The drug and polymer were not interacting with each other.  The particles
were smooth, spherical and and homogeneous external aspects. The crystallinity of
nanoparticles was less than pure Glipizide. The selected formulation for dissolution
study shows 209.6 nm size and 95.66±1.70 percent encapsulation efficiency. In vitro
release was found to be much sustained up to seven days (64.79±2.68) and follow first
order kinetic. The sustained release naoparticles decreased the blood glucose level up
to  132.66±9.83  mg/dL  in  seven  days  study  period.   The  sustained  release
nanoparticles  of  glipizide could  be  able to  manage type  II  diabetes  mellitus  with
reduced dose frequency, decreased side effects and improve patient compliance.
     Thommey P Thomas51 et al.,(2012)  described nanoparticle drug delivery might
improve  the  therapeutic  response  to  anticancer  drugs  and  allow the  simultaneous
monitoring of drug uptake by tumors.  Acetylated dendrimers were conjugated to folic
acid as a targeting agent and then coupled to either Methotrexate or Tritium and either
Fluorescein or 6-Carboxytetramethylrhodamine. These conjugates were injected i.v.
into immunodeficient mice bearing human KB tumors that overexpress the folic acid
receptor.  In  contrast  to  nontargeted  polymer,  folate-conjugated  nanoparticles
concentrated in the tumor and liver tissue over 4 days after administration. The tumor
tissue  localization  of  the  folate-targeted  polymer  could be  attenuated  by prior  i.v.
injection of free folic acid. Targeting Methotrexate increased its antitumor activity and
markedly decreased its toxicity,  allowing therapeutic responses not possible with a
free drug.   
               Amrita Dikpati 52 et al.,(2013)   explained the use of nanoparticles as carrier
system for drugs to cross the barriers of the CNS. Different types of nanoparticles,
their  methods of production and methods for  the characterization of  nanoparticles
have been discussed. There is a need to develop effective, preferably bio degradable,
as well as safe nanoparticulate drug delivery systems, which is to be developed, is
discussed under future prospect. A list of research work conducted in the field of CNS
targeted drug delivery using nanoparticles has been provided encompassing the work
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of research groups in the above review article along with recent patents and FDA
approved products. 
Sarah D.brown53et al.,(2010) studied the platinum-based anticancer drugs Cisplatin,
Carboplatin,  and Oxaliplatin are an important  component of chemotherapy but are
limited by severe dose-limiting side effects and the ability of  tumours  to  develop
resistance rapidly.  These drugs can be  improved through the use of  drug-delivery
vehicles that are able to target cancers passively or actively. The active component of
the anticancer  drug oxaliplatin to  a  gold nanoparticle  for  improved drug delivery.
Naked gold nanoparticles were functionalized with a thiolated poly(ethylene glycol)
(PEG)  monolayer  capped  with  a  Carboxylate  group.  The  platinum-tethered
nanoparticles  were examined for  cytotoxicity,  drug uptake,  and localization in the
A549 lung epithelial cancer cell line and the colon cancer cell lines HCT116, HCT15,
HT29, and RKO. The platinum-tethered nanoparticles demonstrated as good as, or
significantly better, cytotoxicity than oxaliplatin alone in all of the cell lines and an
unusual ability to penetrate the nucleus in the lung cancer cells.
May  D  wang54et  al.,(2007)  developed  Cancer  nanotechnology  is  currently  under
intense  development  for  applications  in  cancer  imaging,  molecular  diagnosis  and
targeted  therapy.  The  basic  rationale  is  that  nanometer-sized  particles,  such  as
biodegradable  micelles,  semiconductor  quantum dots  and  iron  oxide  nanocrystals,
have functional or structural properties that are not available from either molecular or
macroscopic  agents.  When  linked  with  biotargeting  ligands,  such  as  monoclonal
antibodies,  peptides  or  small  molecules,  these  nanoparticles  are  used  to  target
malignant tumours with high affinity and specificity. In the ‘mesoscopic’ size range of
5–100 nm in  diameter,  nanoparticles  also  have  large  surface  areas  and  functional
groups for conjugating to multiple diagnostic (e.g., optical, radioisotopic or magnetic)
and therapeutic (e.g., anticancer) agents. Recent advances have led to multifunctional
nanoparticle  probes  for  molecular  and  cellular  imaging,  nanoparticle  drugs  for
targeted therapy, and integrated nanodevices for early cancer detection and screening.
These developments have opened exciting opportunities for personalized oncology in
which  cancer  detection,  diagnosis  and  therapy  are  tailored  to  each  individual’s
molecular  profile,  and  also  for  predictive  oncology,  in  which  genetic/molecular
information is used to predict tumor development, progression and clinical outcome.
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Jayanth panyam55et al.,(2002) reported the rapid (<10 min) endo-lysosomal escape
of  biodegradable  nanoparticles  (NPs)  formulated  from the  copolymers  of  poly(dl-
lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal
of the surface charge of NPs (from anionic to cationic) in the acidic endo-lysosomal
compartment, which causes the NPs to interact with the endo-lysosomal membrane
and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic
agents, including macromolecules such as DNA and low molecular weight drugs such
as  Dexamethasone,  intracellularly  at  a  slow  rate,  which  results  in  a  sustained
therapeutic effect. 
Dong M.Shin56et al.,(2008) designed to improve the biodistribution of cancer drugs,
nanoparticles for optimal size and surface characteristics to increase their circulation
time in the blood stream. They are also able to carry their loaded active drugs to
cancer cells by selectively using the unique pathophysiology of tumours, such as their
enhanced  permeability  and  retention  effect  and  the  tumor  micro  environment.  In
addition to this passive targeting mechanism, active targeting strategies using ligands
or antibodies directed against selected tumor targets amplify the specificity of these
therapeutic  nanoparticles.  Nanoparticles  have  the  ability  to  accumulate  in  cells
without being recognized by P-glycoprotein, one of the main mediators of multidrug
resistance,  resulting  in  the  increased  intracellular  concentration  of  drugs.
Multifunctional and multiplex nanoparticles are now being actively investigated and
are on the horizon as the next generation of nanoparticles, facilitating personalized
and tailored cancer treatment.
M.A.Khan57 et al.,(2002)  Prepared Nanoparticles (NP) are solid colloidal particles
ranging in size from 1 to 1000 nm that are utilized as drug delivery agents. The use of
NPs to deliver drugs to the brain across the Blood-Brain Barrier (BBB) may provide a
significant  advantage  to  current  strategies.  The  primary  advantage  of  NP carrier
technology is  that  NPs mask the blood-brain barrier limiting characteristics of the
therapeutic  drug molecule.  Furthermore  this  system may slow drug release in  the
brain,  decreasing  peripheral  toxicity.  Influencing  manufacturing  factors  (type  of
polymers and surfactants, NP size, and the drug molecule) are detailed in relation to
movement of the drug delivery agent across the BBB. Currently, reports evaluating
NPs  for  brain  delivery  have  studied  anaesthetic  and  chemotherapeutic  agents.
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Physiological factors such as phagocytic activity of the reticuloendothelial system and
protein opsonization may limit the amount of brain delivered drug and methods to
avoid  these  issues  are  also  discussed.  NP technology  appears  to  have  significant
promise in delivering therapeutic molecules across the BBB.
Brian G.Trewyn58 et al.,(2008) Prepared A Boronic acid-functionalized Mesoporous
silica  nanoparticle-based  drug  delivery  system  (BA-MSN)  for  glucose-responsive
controlled release of both insulin and cyclic adenosine monophosphate (cAMP) was
synthesized.  Fluorescein  isothiocyanate-labeled,  gluconic  acid-modified  Insulin
(FITC-G-Ins) proteins were immobilized on the exterior surface of BA-MSN and also
served as caps to encapsulate cAMP molecules inside the mesopores of BA-MSN.
The release of both G-Ins and cAMP was triggered by the introduction of saccharides.
The selectivity of FITC-G-Ins release toward a series of carbohydrate triggers was
determined to be fructose > glucose > other saccharides. The unique feature of this
double-release system is that the decrease of FITC-G-Ins release with cycles can be
balanced by the release of cAMP from mesopores of MSN, which is regulated by the
gatekeeper effect of FITC-G-Ins. In vitro controlled release of cAMP was studied at
two pH conditions (pH 7.4 and 8.5). Furthermore, the cytotoxicity of cAMP-loaded
G-Ins-MSN  with  four  different  cell  lines  was  investigated  by  cell  viability  and
proliferation studies. 
Sunil A.Agnihotri59 et al.,(2004) reviewed outlines the major new findings on the
pharmaceutical  applications  of  chitosan-based  micro/nanoparticulate  drug  delivery
systems published over the past decade. Methods of their preparation, drug loading,
release characteristics, and applications are covered. Chemically modified chitosan or
its derivatives used in drug delivery research are discussed critically to evaluate the
usefulness  of  these  systems  in  delivering  the  bioactive  molecules.  The  research
activities  on  chitosan  micro/nanoparticulate  systems  containing  various  drugs  for
different therapeutic applications have increased at the rapid rate.
C.Schwarz60 et  al.,(1999)  Solid  lipid  nanoparticles  (SLN)  are  a  colloidal  carrier
system  for  controlled  drug  delivery.  The  lipophilic  model  drugs  Tetracaine  and
Etomidate  were  incorporated  to  study  the  maximum  drug  loading,  entrapment
efficacy, effect of drug incorporation on SLN size, zeta potential (charge) and long-
Dept. pharmaceutics. K.M College Of Pharmacy, Madurai
Page 38
Literature review
term  physical  stability.  Drug  loads  of  up  to  10%  could  be  achieved  whilst
simultaneously maintaining a physically stable nanoparticle dispersion. Incorporation
of drugs showed no or little effect on particle size and zeta potential compared to
drug-free SLN. The optimized production parameters previously established for drug-
free SLN dispersions can therefore be transferred to drug-loaded systems to facilitate
product development.
Abdul kareem61 et al .,(2010) studied invitro and invivo pharmadynamic activity of
newly synthesized palm oil  ester  (POES)  based  nanocream contain Piraxicam for
topical delivery.       Growing interest in use of topical vehicle systems assist in drug
permeation through skin, drug of interest are usually those that are problematic. When
given orally, such as Piraxicam, a highly effective anti-inflammatory,anti-pyretic and
analgesic but with the side effect of causing gastro intentional ulcers. 
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3. RESEARCH ENVISAGED
3.1  AIM OF THE WORK
 The purpose of this research work was to prepare Furosemide nanoparticles to
reduce dosing frequency.
 Polymeric nanoparticles have received more attention for preparing sustained
release  dosage  forms  because  of  their  inertness,  solubility  in  relatively  non-toxic
solvent. 
 Furosemide is a loop diuretic used in the treatment of congestive heart failure,
edema, renal failure etc.,
Polymeric  nanoparticles  are  one  of  the  more  powerful  platforms  to  attain
prolonged release. Since Furosemide has short life time 1 to 1.7 hrs. This research
work is focused on the preparation of nanoparticles. By using this Eudragit RL 100 is
taken on a release retardant material.
Formulation  of  Eudragit  RL 100  nanoparticles  of  Furosemide  to  achieve
sustain action, with increasing absorption and thereby to increase it bio-availability.
The  slow and  constant  release  of  Furosemide  from nanoparticles  maintain
constant drug plasma concentration thereby increasing therapeutic efficacy.
The  developed  formulation  overcome  and  alleviation  the  draw  back  and
limitations of Furosemide sustained release formulation.   
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                                          3.2   PLAN OF THE WORK
       Plan of the work involves the following process:
● Pre formulation studies for raw materials observed.
● Formulation of Furosemide loaded Eudragit RL100 nanoparticles can be prepared
by solvent evaporation method.
● FT-IR study will be use for comparison of nanoparticles of preparation with its
raw materials.
● The  optimized  formulation  will  be  selected  based  on  the  results  of  following
parameters. The prepared nanoparticles can be evaluated by following chemical
characteristics:
● Drug content determination.
● Drug entrapment efficiency.
● In-vitro drug release of formulated nanoparticles .
● The morphology of nanoparticle was  by scanning electron microscopy (SEM)
●  Zeta potential analysis of the optimized formulation.
● Drug release kinetic study
● Stability studies for the optimized formulation at different temperature.
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4.0 METHODOLOGY
Table 7.   INSTRUMENTS AND MATERIALS USED:
S.NO         EQUIPMENTS            SOURCE
1 Vortex Mixer   Remi motors Ltd, Mumbai.
2 Rotary flash evaporator   Equitron, Mumbai.
3 Probe sonicator   Bandelin, Germany.
4 Magnetic stirrer   Remi motors Ltd. Mumbai.
5 Single beam UV spectrophotometer   Shimadzu corporation, Japan.
6 Electronic balance   Shimadzu, Singapore.
7 Stability chamber   Osword, Mumbai.
8 Ultra centrifugation   Remi motors Ltd, Mumbai.
9 pH – meter   Elico Pvt, Chennai.
10 FTIR spectroscopy   Perkin Elmer, Germany.
11 Autoclave   Kemi chem., India.
12 Double beam UV spectrophotometer   Perkin Elmer, Germany
13 Laminar air flow   Klenzaids, Mumbai.
14 Incubator   M.C.DAAL&CO, Mumbai.
15 Freeze drier   Allied frost, Mumbai.
16 Hot air oven   Biochemicals, Mumbai.
17 Membrane filter   Gotting Ltd, Germany
18 ZEISS   Oberkochen, Germany.
19 Malvern   RHS Malvern, United kingdom.
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Table 8.   MATAERIALS USED
     MATERIALS      SOURCE
Furosemide gsk pharma, Mumbai.
Eudragit RL 100 Micro labs ,Hosur.   
Sodium dodecyl sulphate S.D.Fine chemicals,Boisar.
Ethanol S.D.Fine chemicals,Boisar.
Potassium dihydrogen phosphate S.D.Fine chemicals,Boisar.
Disodium hydrogen phosphate S.D.Fine chemicals,Boisar.
Sodium Hydroxide S.D.Fine chemicals,Boisar.
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4.1 DRUG PROFILE62
FUROSEMIDE:
Structure:
Molecular formula:
C12H11ClN2O5S
Chemical name:
4-chloro-2-( furan-2-ylmethylamino )-5-sulfamoyl benzoic acid
Molecular weight:
330.745 g/mol
Mechanism of action:
     Furosemide, like other loop diuretics, acts by inhibiting NKCC2, the luminal
Na-K-2Cl symporter in the thick ascending limb of the loop of Henle. The action on
the distal tubules is independent of any inhibitory effect on carbonic anhydrase or
aldosterone;  it  also  abolishes  the  corticomedullary  osmotic  gradient  and  blocks
negative, as well as positive, free water clearance.
Because of the large NaCl absorptive capacity of the loop of Henle, diuresis is
not limited by development of acidosis, as it is with the carbonic anhydrase inhibitors.
By inhibiting the transporter, the loop diuretics reduce the reabsorption of NaCl and
also  diminish  the  lumen-positive  potential  that  derives  from  K+  recycling.  This
electrical potential normally drives divalent cation reabsorption in the loop, and by
reducing this potential, loop diuretics cause an increase in Mg2+ and Ca2+ excretion.
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Prolonged use can cause significant hypomagnesemia in some patients. Since Ca2+ is
actively reabsorbed in the distal convoluted tubule, loop diuretics generally do not
cause hypocalcemia.
Additionally,  Furosemide  is  a  noncompetitive  subtype-specific  blocker  of
GABA-A receptors. Furosemide has been reported to reversibly antagonize GABA-
evoked currents of α6β2γ2 receptors at µM concentrations, but not α1β2γ2 receptors.
During  development,  the  α6β2γ2  receptor  increases  in  expression  in  cerebellar
granule neurons, corresponding to increased sensitivity to furosemide.
Pharmacokinetics:
Molecular weight (Daltons) 330.7
Protein binding 91–99%
Excreted unchanged in urine 80–90%
Volume of distribution (L/kg) 0.07–0.2
Half-life – normal/ESRF (hrs) 0.5–2/9.7
 Drug interactions:
Potentially hazardous interactions with other drugs:
Analgesics:  increased risk of  nephrotoxicity with NSAIDs; antagonism of  diuretic
effect with NSAIDs
Anti-arrhythmics:  risk  of  cardiac  toxicity  with  anti-arrhythmics  if  hypokalaemia
occurs; effects of Lidocaine and Mexiletine antagonised
Antibacterials: increased risk of ototoxicity with Aminoglycosides, Polymyxins and
Vancomycin; avoid concomitant use with Lymecycline
Antidepressants:  increased  risk  of  hypokalaemia  with  Reboxetine;  enhanced
hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics
Anti-epileptics: increased risk of hyponatraemia with Carbamazepine
Antifungals: increased risk of hypokalaemia with Amphotericin
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Antihypertensives:  Enhanced  hypotensive  effect;  increased  risk  of  first  dose
hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with
Sotalol if hypokalaemia occurs
Antipsychotics:  Increased  risk  of  ventricular  arrhythmias  with  Amisulpiride,
Sertindole  or  Pimozide  (avoid  with  Pimozide)  if  hypokalaemia  occurs;  enhanced
hypotensive effect with Phenothiazines
Atomoxetine: Hypokalaemia increases risk of ventricular arrhythmias
Cardiac glycosides: Increased toxicity if hypokalaemia occurs
Ciclosporin:  variable  reports  of  increased  nephrotoxicity,  ototoxicity  and
hepatotoxicity
Lithium: risk of toxicity.
Route:
IV peripherally or centrally, IM, oral.
1 hour; not greater than 4 mg/minute 
250  mg  to  50  ML sodium  chloride  0.9%  or  undiluted  via  CRIP  (Cysteine-rich
intestinal protein)
Increased  danger  of  ototoxicity  and  nephrotoxicity  if  infused  at  faster  rate  than
approximately 4 mg/min.
Protect from light 
Medical uses:
            Furosemide is primarily used for the treatment of hypertension and edema. It
is the first-line agent in most people with edema caused by congestive heart failure. It
is also used for hepatic cirrhosis, renal impairment, nephrotic syndrome, in adjunct
therapy for cerebral/pulmonary edema where rapid diuresis is required (IV injection),
and  in  the  management  of  severe  hypercalcemia  in  combination  with  adequate
rehydration.
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Doses:
     Hypertension:
Adult: 40-80 mg daily
   Odema associated with heart failure:
Adult: Initially 20 mg daily or 40 mg once daily
Severe case: 600 mg
Child: 1-3 mg/kg daily
Adverse effects:
Although disputed,  it  is  considered ototoxic:  "usually with large parenteral
doses and rapid administration and in renal impairment". Furosemide also can lead to
gout caused by hyperuricemia. Hyperglycemia is also a common side effect.
            The tendency,  as for all  loop diuretics, to cause low potassium levels
(hypokalemia) has given rise to combination products,  either with potassium itself
(e.g. Lasix-K) or with the potassium-sparing diuretic Amiloride (Co-Amilofruse).
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4.2  POLYMER PROFILE63
EUDRAGIT RL 100
Ammonia-methacrylate polymers, consist of fully polymerized copolymers of
acrylic acid and methecrylic acid ester with a low content of primary amino group as
described by NF XVII.
 Molecular weight: 150.000
Functional category: Film former, Tablet diluents
Application in pharmaceutical formulation and technology:
Used to form water insoluble film or film coats for sustained release product,
these are also permeable to solvents .
Description:
It is referred as ammonia methacrylate co polymer in the USPNF mono graph,
are co-polymer synthesized from acrylic acid and methacrylic acid ester having 100%
of functional quaternary ammonium group. The ammonium group is present as salt,
and give rise to pH-independent permeability of polymer and it is water insoluble, and
film prepared from Eudragit L 100 is freely permeable to water.
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Chemical Name:
Poly (ethyl  acrylate,  methyl  methacrylate,  triethylamino  ethyl  methacrylate
chloride).
Solubility in various solutions:
Soluble  in  various  alcohols  like  ethanol,  methanol,  and  propan-2-ol,
dichloromethane, solvent  ethyl  acetate.  Insoluble or  immiscible in  petroleum ether
and water.
Plasticizer: 
This includes dibutyl phthalate, poly ethylene glycols, and triethyl citrate .
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5.0 EXPERIMENTAL INVESTIGATIONS
5.1 CONSTRUCTION OF STANDARD CURVE FOR FUROSEMIDE
A. By UV spectroscopy Method64 :
Furosemide is estimated spectrophotometrically at 271nm and it obeys Beer-
lambert’s Law of 1-10µg/ml.
Determination of absorbance maximum ( ʎmax )
Furosemide  was  dissolved  in  phosphate  buffer  saline  pH  7.4solution  with
20µg/ml concentration was prepared by suitable dilution. The solution was scanned in
UV spectrophotometer  at  200 to  400nm using  phosphate  buffer  saline  pH 7.4  as
blank.  Absorbance  maximum  was  determined  as  271nm65.The  drug  was  later
quantified by measuring the absorbance at 271nm in phosphate buffer saline pH 7.4.
Preparation of pH 7.4 phosphate buffer saline66
Disodium hydrogen phosphate 2.38gm, potassium phosphate 0.19gm, sodium
hydroxide  8gmweighted  and  it  is  transformed  into  1000ml  volumetric  flask  and
volume is made up with distilled water. The pH was adjusted if necessary.
Preparation of stock solution
Stock  solution was  prepared  by dissolving 100mg of  Furosemide  drugs  in
100ml  of  solvent  medium,  so  as  to  get  a  solution  of  1000  µg/ml  concentration
(primary  stock  solution)  from  primary  stock  solution  1ml  was  taken  in  100  ml
standard flask and a diluted to 100 ml with solvent medium PBS 7.4 (secondary stock
solution) to get the concentration of 1-10mcg/ml.
Preparation of standard solution
From the secondary stock solution aliquots from 1 to 10 ml PBS to get the
final  concentration  ranges  from  1  to  10  µg/ml.  Absorbance  of  the  solution  was
measured at 271nm UV spctrophotometrically against drug free PBS pH 7.4 media as
blank.
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                        Table 9.  CALIBRATION CURVE OF FUROSEMIDE 
S.NO Concentration (µg/ml ) Absorbance at 271 nm
1 1 0.041
2 2 0.070
3 3 0.102
4 4 0.131
5 5 0.160
6 6 0.191
7 7 0.219
8 8 0.248
9 9 0.275
10 10 0.301
Fig No:1  STANDARD CURVE FOR FUROSEMIDE
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PRE FORMULATION STUDY
5.2  DRUG AND POLYMER COMPATIBILITY STUDY BY FTIR 
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One of the requirements for the selection of suitable excipient (or) carrier for
pharmaceutical formulations is compatibility. Therefore in the present in the present
work,  a  study  was  carried  out  using  fourier  transformed  infrared  (FT-IR)
spectrophotometer  (using  perkin  elmer)  to  confirm  of  any  possible  chemical
interaction between the Furosemide and Eudragit RL 100.
Infrared spectroscopy by potassium pellet  method was carried  out  on pure
substance (Furosemide, Eudragit RL 100) separately and their physical mixture. They
are compressed under 15 tonnes pressure in a hydraulic press to form a transparent
pellet. The pellet was scanned from 4000 to 400 cm-1 in a spectrophotometer.
The spectrum of physical mixture was compared with the original spectra to
determine any possible molecular interactions between the drug and polymer. Fourier
Transformer Infrared Spectroscopy (FTIR) analysis measure the selective absorption
of  light  by  the  vibration  modes  of  specific  chemical  bonds  in  the  sample.  The
observation  of  vibration  spectrum  of  encapsulated  drug  by  evaluates  the  kind  of
interaction occurring between the drug and polymer. 
In the presence work, Furosemide pure drug, pure Eudragit RL 100 was carry
out to FTIR and spectra are obtaine . They are compressed under 15 tonnes pressure
in a hydraulic press to form a transparent pellet. The pellet was scanned from 4000 to
400 cm-1 in a spectrophotometer. 
Table 10.IR SPECTRA DATA FOR PURE DRUG FUROSEMIDE
                 Frequency cm-1           Groups Assigned
508.38-590.11   Cl-Cl – stretching
1672 – 1780   C=O – stretching
1640 – 1680   C=C – stretching
3300 – 3500   NH  - stretching
2850 – 2960   CH – stretching
Table 11.  IR SPECTRA DATA FOR PHYSICAL MIXTURE
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Frequency cm-1 Group Assigned
                   583.37          Cl – Cl - Stretching
                   3429.19          OH - Stretching
                   1718.21          C=O - Stretching
                   2852.63          CH - Stretching
REPORT:
In FTIR spectra the peaks of physical mixture was compared with the original
spectra.  Same  peaks  were  observed,  there  is  no  possible  molecular  interaction
between the drug and the polymer. 
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5.3 METHOD OF PREPARATION OF FUROSEMIDE NANOPARTICLES
 Solvent Evaporation Method67
All batches of nanoparticles were prepared by solvent evaporation method.
The required quantity of drug and polymer dissolved in 5ml ethanol (I portion) and 50
mg of sodium dodecyl sulphate dissolved in 5 ml of water, this mixture well dissolved
(II portion). Then, the sodium dodecyl sulphate solution mixed with drug, polymer
mixture by syringe. This mixture was homogenized by vortex mixture for 1 min and
then sonicated set  at  90W of energy output for  size reduction. Then nanoparticles
were collected after solvent drying by flash evaporator.
                  Table 12. Method of preparation of Furosemide nanoparticles
S.NO Formulation code Drug (Furosemide) in
mg
Plymer Eudragit
RL 100
1 F1 20 10
2 F2 20 20
3 F3 20 30
4 F4 20 40
5 F5 20 50
6 F6 20 60
7 F7 20 70
8 F8 20 80
9 F9 20 90
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10 F10 20 100
 
5.4 EVALUATION OF NANOPARTICLES 
  5.4.1 DRUG ENTRAPMENT STUDY67
      The efficiency study was determined by free drug content in the supernatant
which is obtained after centrifuging the solid lipid suspension at (15,000rpm for 20
min at 0°C using ultra centrifuge) The absorbance was measured at 271 nm by UV
spectrophotometrically .
 5.4.2 INVITRO DRUG RELEASE STUDIES 68,33
   BY UV SPECTROPHOTOMETRIC METHOD 
The invitro drug release study was carried out by using diffusion membrane
technique. The nanoparticles preparation was placed in a dialysis membrane and it is
dropped into a beaker containing 200 ml of diffusion medium (phosphate buffer saline
7.4) the medium was maintained at 37oC under magnetic stirring at constant speed .At
fixed time interval 1ml of sample was taken from the diffusion medium for every 1
hour and it was replaced by 1ml fresh medium. This process was carried out for 24
hours. The sample was measured UV spectrophotometrically at 271nm. The 
5.4.3 SCANNING ELECTRON MICROSCOPY ( SEM )70,24
The optimized  formulation  was  morphologically  characterized  by scanning
electron  microscopy  (SEM)  .the  sample  for  SEM  analysis  was  mounted  in  the
specimen using an adhesive small sample wad mounted directly in scotsch double
adhesive  tape.  The sample  was  analyzed  in  hitachi  scanning  electron  microscopy
operated at 15Kv photograph was taken.
5.4.4 SURFACE CHARGE ( ZETA POTENTIAL ) DETERMINATION71,45
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Zeta potential is an important parameter to evaluate and establish an optimum
condition for stability of colloidal or dispersed systems. The prepared nanoparticle
suspension were characterized with respect to zeta potential by using zeta potential
analyser (Malvern Zeta Seizer).zeta potential is electrical charges on particles surface
it create electrical barrier it is very important for drug stability. The effect of Eudragit
RL 100 on the surface characterized of the nanoparticle was studied.
5.4.5 pH AND PHYSICAL APPEARANCE
The pH of the formulation was measured using pH meter. It plays a vital role
in  process  of  stability  and  formulation  activity  .The  physical  appearance  of  the
formulation  such  as  color  and  suspended  foreign  particulate  matter  were  to  be
examined.
5.4.6 STABILITY STUDIES OF NANOPARTICLES72 
The  stability  studies  of  nanoparticles  involve  observing  the  formulation  at
45oC/70%  RH  which  accelerated  condition  and  4oC  on  refrigerator  and  room
temperature.  The formulations were kept in both the temperature for 3 month and
sufficient  amount  of  sample  were  taken  at  perotic  intervals  for  per  formic  the
following tests,
a. Physical appearance
b. pH of the solution
c. In vitro drug release ( Dissolution )
d. Percentage of drug entrapment
5.4.7 KINETICS OF DRUG RELEASE
The  optimized  formulation  subjected  to  graphical  treatment  to  assess  the
kinetic of drug release.
Zero order plot:
The optimized formulation is most suitable for parental administration as it
founds to be good in the in vitro release kinetic study. The zero order plot obtained
plot by plotting cumulative % drug release versus time
Higuchi plot:
Dept. Pharmaceutics. K.M College Of Pharmacy,Madurai.
Page 58
Experimental Investigation
The higuchi plot made by plotting cumulative %drug release versus square root of
time. 
Korsemeyer plot:
The graph obtained by log cumulative % drug release versus log time.
First order plot:
The graph obtained by log drug remaining versus log time.     
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6.0 RESULTS AND DISCUSSION
 DEVELOPMENT OF FUROSEMIDE NANOPARTICLES:
In this study, Furosemide nanoparticles were prepared by solvent evaporation
method by using Eudragit RL 100. Drug (Furosemide) and Polymer (Eudragit  RL
100)  (1:5)  dissolved  in  ethanol.  In  other  hand  0.50mg  sodium  dodecyl  sulphate
dissolved in 5ml water,then two solution were mixed. This mixture was homogenized
by vortex for 1min and then probe sonication. Then this preparation evaporated by
flash rotator evaporator for 20min.
Formulation  with  different  ratios  of  polymer  was  prepared.  Several
physicochemical  characteristics  of  nanoparticles  such  as  morphology,  particle  size
determination,  drug  release  profile  were  investigated  and  stability  of  optimized
formulation at various temperatures were evaluated.
 DRUG & POLYMER COMPATABILITY STUDIES BY FTIR:
Pressed pellet technique was used to handle the sample in FTIR spectrometer.
In  this  technique  a  pinch  of  sample  was  mixed  with  potassium bromide  and  the
mixture was pressed with special discs under high pressure into a transparent pellet
and then inserted in to special holder of IR spectrometer.
IR spectrums for pure drug alone and physical mixture of drug and polymers
are taken. The spectrum of physical mixture was compare with spectrum of pure drug.
Bands seen in pure drug also recognized in physical  mixture,  hence there  was  to
significant interaction between drug and excipients.
 ENTRAPMENT EFFICIENCY OF NANOPARTICLE: 
The Entrapment efficiency of Furosemide loaded nanoparticles were  analyzed
by dialysis method.
The formulation F1, F2, F3  polymer (Eudragir RL100) concentration 10mg,
20mg,  30mg is  taken.  The entrapment  efficiency was  49%±0.14,  56%±0.11,  61%
±0.12 respectively. which shows less repulsive force between drug and polymer. 
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Table 13.Entrapment efficiency of nanoparticles
S.NO Formulation  code Drug
(mg)
Eudragit   RL 100
(mg)
Entrapment
efficiency (%)
1 F1 20 10 49±0.14
2 F2 20 20 56±0.11
3 F3 20 30 61±0.12
4 F4 20 40 67±0.09
5 F5 20 50 71±0.17
6 F6 20 60 77±0.12
7 F7 20 70 83±0.11
8 F8 20 80 88±0.08
9 F9 20 90 94±0.05
10 F10 20 100 45±0.04
  
Then further formulation F4, F5, F6  changes in polymer (Eudragit RL100)
concentration as 40mg,50mg,60mg. The entrapment efficiency was 67%±0.12, 71%
±0.17, 77%±0.12 which also shows less repulsive force between drug and polymer.
So, further increase the concentration of polymer of formulation F7, F8, F9
polymer  (Eudragit  RL100)  concentration  as  70mg,  80mg,  90mg  is  taken.  The
entrapment efficiency was 83%±0.1, 88%±0.08, 94%±0.05. The formulation F9 gives
high percentage  efficiency 94%.which  indicates  the steady increase  in  entrapment
efficiency.
Further study was carried out F10 changes in polymer concentration 100mg
Eudragit  RL100.  Entrapment  efficiency  decreased  to  45%±0.04  due  to  higher
concentration  of  polymer.   From  the  above  result  formulation  F9  shows  highest
percentage  of  entrapment  efficiency  of  94%,  so  formulation  F9  was  selected  for
further studies.
 IN VITRO DRUG RELEASE PROFILE OF NANOPARTICLES
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● The in vitro drug release of Furosemide nanoparticle carried out by membrane
diffusion method and in vitro drug release study was carried out for 24 hours .
● The in vitro drug release of Furosemide loaded nanoparticles with Eudragit RL
100 polymer.
● The in vitro drug release of formulation F1( Furosemide 20mg,Eudragit RL100
10mg) .  The percentage of  drug release was 98.43% in 6 hours.  Formulation
releases the drug in 6 hours. 
● So,  further  formulation  F2,  F3  with  different  concentration  of  polymer
(Furosemide 20mg with Eudragit RL 100 20mg, 30mg) the percentage of drug
release was respectively 97.44%, 96.43% in 8 hours. Which formulations were
shows quick release (8hours).  Due to very low concentration of polymer. 
● The  formulation  F4,  F5,  F6,  F7  carried  out  with  increase  the  polymer
concentration the percentage of drug release was, 98.46 in 13 hours, 98.46% in
15 hours, 96.45% in 19hours, 98.47% in 20 hours, due to less repulsive force.
● The formulation F8, F9 with increase the concentration of polymer concentration
the percentage of drug release was 92.43 % in 24 hours, 98.47 in hours.
● The  formulation  F10  (Furosemide  20  with  Eudragit  RL  100  200mg)the
percentage of drug release was 55.27% in 24 hours . the drug release is 55.27%
due to increase the polymer concentration.
● From the above all formulations ( F1-F10 ) It confirms that the percentage of
drug  release  was  satisfactory  in  formulation  F9  (20mg  of  Furosemide  with
180mg of Eudragit RL 100) Drug release was 98.47% ,so it was decided to be
optimized formulation for further study.
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Table 14.    In vitro drug release for F1
S.NO Amount  of  drug
release   (mg)
% of drug release Cumulative % drug
release
1 2.2 2.3 23
2 3.8 3.81 38.10
3 5.5 5.51 55.19
4 7.3                7.37 73.27
5 8.6 8.63 86.35
6 9.8 9.84 98.43
Fig No:2   IN VITRO DRUG RELEASE FOR FORMULATION F1
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Table 15.   In vitro drug release for F2
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   Time
   (Hrs)
Amount  of  drug
release (mg)
%  of  drug
release
Cumulative  %  drug
release
1 2.0 2.0 20
2 3.2 3.22 32.2
3 4.5 4.51 43.16
4 5.4 5.42 54.22
5 6.9 6.92 66.27
6 8.0 8.03 78.30
7 8.9 8.94 89.40
8 9.7 9.74 97.44
Fig No : 3         IN VITRO DRUG RELEASE FOR FORMULATION F2
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Table 16.   In vitro drug release for F3
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   Time
   (Hrs)
Amount  of
drug  release
(mg)
% of drug release Cumulative  %  drug
release
1 1.8 1.8 18
2 2.9 2.90 29.09
3 4.1 4.14 41.14
4 5.2 5.22 52.20
5 6.7 6.72 67.26
6 7.7 7.73 77.33
7 8.6 8.63 86.38
8 9.6 9.64 96.43
Fig No: 4  IN VITRO DRUG RELEASE FOR FORMULATION F3
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Table 17.   IN VITRO DRUG RELEASE FOR F4
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   Time
   (Hrs)
Amount of  drug
release (mg)
% of drug release Cumulative  %  drug
release
1 1.0 1.0 10
2 1.9 1.90 19.05
3 2.6 2.60 26.09
4 3.5 3.51 35.13
5 4.3 4.31 43.17
6 5.6 5.62 56.21
7 6.3 6.32 63.28
8 7.0 7.03 70.31
9 7.7 7.73 77.35
10 8.3 8.33 83.38
11 8.8 8.84 88.41
12 9.2 9.24 92.44
13 9.8 9.84 98.46
Fig No : 5  IN VITRO DRUG RELEASE FOR F4
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Table 18. IN VITRO DRUG RELEASE FOR F5
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   Time
   (Hrs)
Amount of drug
release (mg)
%  of  drug
release
Cumulative % drug release
1 1.0 1.0 10
2 1.7 1.70 17.05
3 2.3 2.30 23.08
4 3.1 3.11 31.11
5 3.8 3.81 38.15
6 4.7 4.71 47.19
7 5.3 5.32 53.23
8 6.1 6.12 61.26
9 6.7 6.73 67.30
10 7.1 7.13 71.33
11 7.8 7.83 78.33
12 8.3 8.33 83.39
13 8.7 8.74 87.41
14 9.3 9.34 93.43
15 9.8 9.84 98.46
Fig No :6 IN VITRO DRUG RELEASE FOR FORMULATION F5
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Table 19.   IN VITRO DRUG RELEASE FOR F6
   Time
   (Hrs)
Amount  of
drug  release
(mg)
Cumulative  amuont  of
drug release
Cumulative  %  drug
release
1 0.8 0.8 8
2 1.3 1.30 13.04
3 1.6 1.60 16.06
4 2.0 2.00 20.08
5 2.5 2.51 25.10
6 2.8 2.81 28.12
7 3.2 3.21 32.14
8 3.7 3.71 37.16
9 4.1 4.11 41.18
10 4.7 4.72 47.20
11 5.1 5.12 51.23
12 5.6 5.62 56.25
13 6.3 6.32 63.28
14 6.8 6.83 68.31
15 7.6 7.63 76.31
16 8.2 8.23 82.38
17 8.6 8.64 86.41
18 9.1 9.14 91.43
19 9.6 9.64 96.45
Fig No : 7      IN VITRO DRUG FOR FORMULATION F6
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Table 20. IN VITRO DRUG RELEASE FOR F7
   Time
   (Hrs)
Amount  of
drug  release
(mg)
% of drug release Cumulative  %
drug release
1 0.6 0.6 6
2 1.1 1.10 11.03
3 1.5 1.50 15.05
4 1.8 1.80 18.07
5 2.2 2.20 22.09
6 2.7 2.71 27.11
7 3.2 3.21 32.13
8 3.7 3.71 37.16
9 4.2 4.21 42.18
10 4.7 4.72 47.21
11 5.3 5.32 53.23
12 5.7 5.72 57.26
13 6.1 6.12 61.28
14 6.6 6.63 66.30
15 7.1 7.13 71.33
16 7.7 7.73 77.35
17 8.3 8.33 83.38
18 8.8 8.84 88.41
19 9.3 9.34 93.44
20 9.8 9.84 98.47
Fig No : 8  IN VITRO DRUG RELEASE FOR FORMULATION F7
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Table 21.   VITRO DRUG RELEASE FOR F8
   Time
   (Hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %  drug
release
1 0.4 0.4 4
2 0.6 0.60 6.02
3 0.9 0.90 9.03
4 1.3 1.30 13.04
5 1.8 1.80 18.06
6 2.3 2.30 23.09
7 2.8 2.81 28.11
8 3.3 3.31 33.14
9 3.8 3.81 38.16
10 4.2 4.21 42.19
11 4.5 4.52 45.22
12 4.9 4.92 49.22
13 5.1 5.12 51.24
14 5.3 5.32 53.25
15 5.8 5.82 58.26
16 6.3 6.32 63.29
17 6.8 6.83 68.31
18 7.1 7.13 71.34
19 7.3 7.33 73.35
20 7.6 7.63 76.36
21 8.0 8.03 80.38
22 8.3 8.34 83.40
23 8.7 8.74 87.41
24 9.2 9.24 92.43
Fig No : 9  IN VITRO DRUG RELEASE FOR FORMULATION F8
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Table 22. I N VITRO DRUG RELEASE FOR F9
   Time
   (Hrs)
Amount  of  drug
release (mg)
% of drug release Cumulative  %
drug release
1 03. 0.3 3
2 0.7 0.70 7.01
3 1.2 1.20 12.03
4 1.6 1.60 16.06
5 2.1 2.10 21.08
6 2.7 2.71 27.10
7 3.2 3.21 32.13
8 3.8 3.81 38.16
9 4.3 4.31 43.19
10 4.6 4.62 46.21
11 5.0 5.02 50.23
12 5.4 5.42 54.25
13 5.8 5.82 58.27
14 6.1 6.12 61.29
15 6.5 6.53 65.30
16 6.9 6.93 69.32
17 7.3 7.33 73.34
18 7.8 7.83 78.36
19 8.1 8.13 81.39
20 8.5 8.54 85.40
21 8.8 8.84 88.42
22 9.1 9.14 91.44
23 9.4 9.44 94.45
24 9.8 9.84 98.47
Fig No : 10  IN VITRO DRUG RELEASE FOR FORMULATION F9
   
0 5 10 15 20 25 30
0
20
40
60
80
100
120
Time in hours
C
u
m
u
la
ti
v
e
 %
 o
f 
d
ru
g
 r
e
le
a
se
Dept. Pharmaceutics. K.M College Of Pharmacy, Madurai.
Result and discussion
   
Table 23. IN VITRO DRUG RELEASE FOR FORMULATION F10
 
0 5 10 15 20 25 30
0
10
20
30
40
50
60
Time in hours
C
u
m
u
la
ti
v
e
 %
 o
f 
d
ru
g
 r
e
le
a
se
Dept. Pharmaceutics. K.M College Of Pharmacy, Madurai.
  Time
   (Hrs)
Amount of drug
release (mg)
% of drug release Cumulative  %  drug
release
1 0.2 0.2 2
2 0.5 0.50 5.01
3 0.7 0.70 7.02
4 0.9 0.90 9.03
5 1.1 1.10 11.04
6 1.3 1.30 13.05
7 1.6 1.60 16.06
8 1.9 1.90 19.08
9 2.0 2.00 20.09
10 2.2 2.21 22.1
11 2.4 2.40 24.01
12 2.7 2.71 27.12
13 2.9 2.91 29.13
14 3.1 3.11 31.14
15 3.2 3.21 32.15
16 3.7 3.71 37.17
17 3.9 3.91 39.18
18 4.1 4.11 41.19
19 4.3 4.32 43.20
20 4.5 4.51 45.12
21 4.7 4.72 47.22
22 5.0 5.02 50.23
23 5.2 52.2 52.25
24 5.5 5.52 55.27
Result and discussion
 SCANNING ELECTRON MICROSCOPY
The  surface  characteristics  of  optimal  formulation  (F9)  particle  size  were
studied  by  scanning  electron  microscopy.  SEM  image  of  prepared  nanoparticle
formulation shows the coating of polymer mixture on drug particle. The appearance
of nanoparticles in scanning electron microscopy in granules form, which indicates a
thin and uniform coating over the drug.
Fig No : 12 SEM FOR F9
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Fig No : 13 SEM FOR F9
Fig No : 14 SEM FOR F9
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 SURFACE CHARGE ( ZETA POTENTIAL )
The potential of a nanoparticle is commonly used to characterize the surface
charge  property  of  nanoparticle.  It  reflects  the  electrical  potential  of  particles  is
influenced  by  the  composition  of  the  particles  and  which  it  is  dispersed.  When
nanoparticle formulation are administrated through intravenous route they are easily
identified and detected by the phagocytes. The particle size and the hydrophobicity
surface of the nanoparticle determine the adsorption of blood components (proteins)
called  as  opsonins.  These  opsonins  in  turn  decide  the  fate  of  the  nanoparticles.
Binding of these opsonins on to the surface is known as opsonization. Non modified
nanoparticles  were  rapidly  opsonized  and  gets  easily  eliminated  from  the  body.
Hence,to increase the likehood of the success in drugtargeting by nanoparticles,it is
necessary to minimize the opsonization and to prolong the circulation of nanoparticles
in vivo .
The zeta potential of the nanoparticle formulation with Eudragit RL 100 which
present in the formulation are de-aggregated and remain same and more stable in the
suspension  and  zeta  potential  (mV)  is  59.0  and  zeta  deviation  (Mv)  is  5.29  and
conductivity  (Ms/CM)  is  0.086.  So  polymer  is  more  suitable  for  nanoparticle
preparation  and  the  result  shows  smooth  surface  character  repelled  action  and  it
decrease the opsonization.
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Zeta Potential Report
V2.2
Malvern Instruments Ltd - @ Copyright 2008
Sample Details
Sample Name: Sample - 1 (Furosemide Nano Particles) 2
SOP Name : mansettings.nano
General Notes :
File Name :KMCP.dts   Dispersant Name : Water
Record Number:8 Dispersant RI : 1.330
Date and Time:Friday, 13 Dec 2013 Viscosity (mpa...) : 0.8872
 Dispersant Dielectric Constant: 78.5
System
Temperature (C) :25.0 Zeta Runs : 12
Count Rate (kcps) :235.2  Measurement Position(mm): 2.00
Cell Description :Clear disposable zeta cell Attenuator: 6
Results
Mean (mV) Area (%) Width (mV)
Zeta Potential (mV) : 59.0 Peak 1: 59.0 100.0 5.29
Zeta Deviation (mV) : 5.29 Peak 2:0.00  0.0 0.00
Conductivity (mS/cm): 0.0866 Peak 3:   0.00  0.0      0.00
Result Quality : Good
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STABILITY STUDIES OF FUROSEMIDE NANOPARTICLES:
The stability studies of optimized nanoparticle formulation F10 was carried
our for 3 months .The test was performed in three conditions 4o C, Room temperature
and 45oC/70% RH. At the time interval of one month the nanoparticle formulation
were evaluated for entrapment efficiency. The stability of nanoparticles formulation
was more stable in refrigerator  (4oC) when compared to room temperature and at
(45oC/70%RH)
Table 24. Stability studies for Furosemide nanoparticle
S.NO Storage
Condition
      Test
parameters
  1st month    2th
month
  3rd month
                
1
    4oC    pH
 colour
Cumulative
%  drug
release
7.4
Clear&
colour less
98.47
7.4
Clear&
colour less
97.25
7.4
Clear  &
colour less
96.88
                
2
  Room
 Temperature
  pH
colour
Cumulative
%  drug
release
7.4
Clear  &
colour less
98.47
7.4
Clear  &
colour less
93.36
7.3
Clear  &
colour less
91.85
                
3
 Acceleration
condition  at
45oC/70O%
RH
7.4
clear&
colour less
95.10
7.3
Clear&
colour less
91.21
7.3
Clear&colour
less
89.24
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Table 25.  In vitro release for optimized formulation F10 stability study at 4oC
          Time
          (Hrs)
Cumulative % drug release
1st month(%) 2nd month 3rd month
1 3 3 2.8
2 7.01 7.01 6.98
3 12.03 12.00 11.96
4 16.06 16.02 15.98
5 21.08 21.04 21.00
6 27.10 27.04 27.00
7 32.13 32.08 31.98
8 38.16 38.02 37.96
9 43.19 43.06 42.92
10 46.21 45.96 45.88
11 50.23 49.90 49.76
12 54.25 53.91 53.63
13 58.27 57.54 5.22
14 61.29 60.88 60.14
15 65.30 64.50 63.96
16 69.32 69.02 68.86
17 73.34 72.14 72.02
18 78.36 78.03 77.95
19 81.39 80.68 80.69
20 85.40 84.66 84.22
21 88.42 87.21 87.01
22 91.44 91.17 91.15
23 94.45 94.02 93.57
24 98.47 97.25 96.88
STABILITY  STUDY  RELEASE  DATA  FOR  FORMULATION  F10
AFTER 3  MONTHS AT 4oC
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Table 26. IN VITRO DATA FOR OPTIMIZED FORMULATION F10
STUDY AT ROOM TEMPERATURE
Cumulative % drug release
Time
(Hrs)
1st month(%) 2nd month 3rd month
1 3 2.8 2.7
2 7.01 6.88 5.12
3 12.03 9.92 8.21
4 16.06 14.98 12.10
5 21.08 19.12 16.14
6 27.10 23.16 21.18
7 32.13 28.20 25.52
8 38.16 34.28 32.58
9 43.19 40.32 37.66
10 46.21 44.42 41.72
11 50.23 48.50 43.78
12 54.25 51.56 47.87
13 58.27 54.63 50.95
14 61.29 57.69 54.02
15 65.30 62.75 59.08
16 69.32 66.55 63.16
17 73.34 71.62 68.22
18 78.36 75.68 72.32
19 81.39 78.76 76.38
20 85.40 80.85 78.48
21 88.42 84.96 81.56
22 91.44 87.06 85.66
23 94.45 90.18 88.72
24 98.47 93.36 91.85
STABILITY STUDY RELEASE DATA FOR FORMULATION F10 AFTER
THREE MONTHS AT ROOM TEMPERATURE
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Table 27. IN VITRO DATA FOR OPTIMIZED FORMULATION F10 STUDY
AT 45OC/75% RH
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Cumulative % drug release
Time
(Hrs)
1st month(%) 2nd month 3rd month
1 3 2.8 2.4
2 7.52 6.44 5.32
3 11.06 10.48 8.39
4 15.14 13.56 11.45
5 19.20 16.62 14.51
6 23.28 19.68 16.58
7 26.36 23.78 19.72
8 30.44 27.86 24.78
9 33.50 29.96 27.83
10 36.56 31.08 29.89
11 40.66 34.16 32.96
12 45.72 38.25 35.21
13 49.21 43.15 36.87
14 54.28 46.06 40.61
15 59.85 59.16 54.31
16 63.21 63.26 58.98
17 68.24 67.06 61.03
18 72.59 71.12 65.13
19 76.29 74.32 69.36
20 80.58 79.21 74.17
21 84.84 82.13 77.16
22 87.21 86.28 81.36
23 91.62 89.26 85.21
24 95.10 91.21 89.24
Result and discussion
IN VITRO DATA FOR OPTIMIZED FORMULATION F10 STUDY AT
45o/75% RH
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Stability Discussion:
The  Stability  tests  were  carried  out  for  a  period  of  3  months  at  various
conditions. The results showed that the formulation remains stable through out the
period of study. 
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 Kinetics of drug release for optimized formulation F10
The  optimized  formulation  F9  was  introduced  into  graphical  treatment  for
kinetics of drug release
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           Regression=0.998
The optimized formulation F10 of nanoparticle is more suitable for parentral
administration it shows good in the in vitro release kinetic study. The zero order plots
were obtained by plotting cumulative percentage drug release. The regression value is
0.998. confirm that it follow zero order release.
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HIGUCHI’S PLOT :
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         Regression = 0.954
Higuchi  plot  was  made  by  plotting  cumulative  %  of  drug  release  against
square root of time. The regression value was found to be 0.954 .This indicates that
diffusion is one of the mechanism of drug release.
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KORSEMEYER PLOT:
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
0
0.5
1
1.5
2
2.5
f(x) = 1.07x + 0.56
R² = 0.99
Log Time
                                                      n=1.073
The graph was plotted between log cumulative % of drug release and log time.
The value was found to be 0.45 < n < 0.89 anomalous (non-fickian) diffusion. This
indicates that the diffusion non-fickian for the mechanism of drug release. 
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FIRST ORDER RELEASE:
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              R=0.571
                   R value indicates that drug release not follow first order kinetics.
Dept. Pharmaceutics. K.M College Of Pharmacy, Madurai.
Summary and Conclusion
7.0 SUMMARY AND CONCLUSION
The present study Furosemide nanoparticle developed a nanoparticulate drug
delivery system of using biodegradable polymer Eudragit RL100.
All batches of nanoparticles (F1-F10) were prepared by solvent evaporation
method.
The entrapment  efficiency of  the  optimized  formulation was  94±0.04,  and
invitro drug release was 98.16 after 24 hours. It also obeys the zero order, follows.
Particle  size  determination  by  Scanning  electron  microscope  shows  the  best
formulation containing size of about 200nm. The stability test performed revealed that
the  formulation  was  good.  The best  formulation  was  examined  for  zeta  potential
determination. 
            The  formulation  F9  showed  maximum  deviation  of  -59mV which
demonstration  that  the  particles  are  separate  and  highly  repelling.  This  repelling
property found to be more useful in decreasing opsonization by membrane filtration
and favours specificity. 
The  Stability  tests  were  carried  out  for  a  period  of  3  months  at  various
conditions. The results showed that the formulation remains stable through out the
period of study. 
The optimized formulation F9 was found to follow zero order release pattern.
Which was revealed by linearity shown from the plot of time versus concentration.
In  future  F9  can  be  subjected  to  bio-equivalence  study  and  suitability  to
market can be decided on that.
Thus  aim  of  the  project  was  achieved  by  optimizing  the  formulation
parameter.  
Dept. Pharmaceutics. K.M College Of Pharmacy, Madurai. Page 
Bibiliography
BIBILIOGRAPHY 
1. N.K. Jain, Targeted delivery of drugs, Advances in controlled and novel drug delivery
1stedition, 2005, pg.no.452.
2. Amarnath  maitra,  T.K.De,  Preparation  of  hydrogel  and  small  hydrogel
nanoparticlesiv reverse micelles, Dabur research foundation ,1996, (10)1, 1-40
3. Ritugihotra,  comparative  review  of  recently  developed  particulate  drug  carrier
system, pharmaceutical information 2009, (11)5, 7-10.
4. Rainer  H.Miller,  Karsten  Mader  and  Sven  Gohla,  Solid  lipid  nanoparticles  for
controlled  drug  delivery,  review  of  the  state  of  art,  European  journal  of
pharmaceutics and biopharmaceutics,2005,(14)9,50,161-177.
5. L  Zhang,  FX  Gu,  Nanoparticles  in  medicine,  Therapeutic  application  and
development, Nature publishing group,vol5,2008.
6.  Jim riviere, Nancy monteiro Science and technology “ New method predicts how
nano-particles  will  react  in  the  human  body  “  north  Carolina  state  university
USA.2008(83)5,761-768.
7. Soumya missula , Micro particulate drug carrier, Review article ,2012,1(1),1-40.
8. Dr. N.K. Jain 2007, Dr. Hari singh Pharmaceutical technology,2009 .Pg.No:452
9.  Xiaoping DV , DIURETICS, Department of pharmacology,2012 ,1-12
10. Katie Herdon, BCPS Pharmacology and clinical use of diuretics2011,1-6.
11. Umar faruksha, T.vetrichelvan, Formulation, Characterization And Optimization Of
Pioglitazone Hydrochloride Nanoparticles By Solvent Displacement Method Using
Factorial Design, International journals of pharma technology,.2010,(5)2,754-766.
12. Heiati H, Tawashi R philis,  Solid lipid nanoparticles as drug carrier,  international
journals of pharmaceutics, 1997:146:123-131. 
13. Kim,Jin-Ki,  Park,Jeong-Sook;  Kim,  Chong-Kook,  Development  of  a  binary lipid
nanoparticles formulation of Itraconazole for parenteral administration and controlled
release, Journal International Journal of Pharmaceutics,2010,383,209-215. 
14. C.X  Song,  V  Labhasetwar, Formulation  and  characterization  of  biodegradable
nanoparticles  for  intravascular  local  drug  delivery,  Journals  of  controlled
release1997, 43,197-212.
15. Cohen-sela, E,Chorny M, Koroukhov N, Danenberg HD, Golomob, G, A new double
emulsion  solvent  diffusion  technique  for  encapsulating  hydrophilic  molecules  in
PLGA nanoparticles.1994,133(2):90-5.
16. D. Dhachinamoorthi, S. Chellaram and P. Shankar, Opthalmic delivey of acyclovir
loaded chitosan nanoparticles, drug and delivery of Indian pharmaceutics,2001,10-
15. 
17. Xinyi  Gu,A,  Novel  approach  to  formulation of  anticancer  drug  on  nanoparticles,
Journals of pharmaceutical science,2008,12,1-149.
Dept. Pharmaceutics Page 95
Bibiliography
18. Ankit  Anand Kharia,  Akhlesh  Kumar  Singhai, Controlled  Release Drug  Delivery
System  with  Stomach  Specific  Mucoadhesive  Nanoparticles,  Pharmaceutics
information science2008,(1)2,1-11.
19.  Jundong Dai,  Tsuneji  Nagai,  Xueqing Wang,  Tao  Zhang,  Meng Meng,  Qiang
Zhang pH-sensitive  nanoparticles  for  improving  the  oral  bioavailability  of
cyclosporine A. 2004, (1)2,229-40.
20. Devarajan  Pv,  Preparation  and  invitro/invivo  evaluation  of  gliclazide  loaded
Eudragit  nanoparticles  as  a  sustained  release  carriers  drug,   Journals  of
development Indian pharma technology,2007,2(33),11-101.
21. Andrei  A.Onischuk,  Tatjana  G,  anti-inflammatory effect  from indomethacin  in
nanoparticles,  Journals  of  aerosol  medicine  and  pulmonary drug  delivery2008,
(3)21,231-244. 
22. F.De  Jaeghere,  Formulation  and  evaluation  of  poorly  water  soluble  HIV-1
protease inhibitors inti pH sensitive nanoparticles, 2006, 116, 1-27.
23. S.Ramesh, D.Ranganayakulu, Design and in vitro characterization of amoxicillin
loaded  sepia  nanoparticles,  Design  and  in  vitro  characterization  of   sepia
nanoparticles 2010,1,65-68.
24. Partha saha, Formulation and evaluation of chitosan based Ampicillin Trihydrate
nanoparticles, International journals of pharmaceutics, 2011, 1-18.
25. Mohammed vaseem, Formulation and evaluation of zinc oxide nanoparticles by
synthesizes by sol-gel method, Implication in drug delivery, International journal
of pharma tech resarch 2005,18,203-212
26. Eliao leo, Invitro evaluation of PLA nanoparticles containing a lipophilic drug in
water soluble or insoluble form, International journal of pharmaceutics,  .2009,
3(36), 114-126.
27. Kathleen Dilloen, vander mooter. Physic chemical characterization & activity of
ciprofloxacin  PLGA  nanoparticles,  factorial  design.  International  journal  of
pharmaceutics 2008,(34)9,234-240.
28. Hannele  Eerika,  Esko  I.Kavappinen,  Preparation  of  polymeric  nanoparticles
contain steroid by novel aerosol flow ractor method, Journal of application of
polymeric nanoparticles, 2010, (5)8,11-121.
29. Rubina mara, Daflon gremiao maria Palmira, Zidovudine loaded PLA and PLA-
PEG blend nanoparticles,  Influence of polymer type on phagocytic  uptake by
polymorphonuclear cells.(2010)395,266-271.
30. Rubiana,C.  Evangelista,  PLGA nanoparticles  containing Praziquentel  effect  of
formulation variables on size distribution, PLGA nanoparticles application 2012,
(8)5,13-45.
Dept. Pharmaceutics Page 96
Bibiliography
31. Esko I. Kauppinen, jukka, synthesis of copolymer-stabilized silver nanoparticles
for coating materials, Journals of science daily, 2005, (1)12,7-12.
32. Yadav  Sc  Biodegradable  polymeric  nanoparticle  based  drug  delivery  system,
Colloids and surfaces, B.Biointerfaces, 2010, 75-98.
33. Roberta cavalli, Otto caputo a, Sterilization and freeze-drying of drug free and
drug  loaded  solid  lipid  nanoparticles,  International  journal  of  pharmaceutics
1997, 148, 47-54.
34. Morteza azhdarzadan, Anti-bacterial performance of Azithromycin nanoparticles
as  colloidal  drug  delivery  system  against  different  gram-negative  &  gram-
positive bacteria. Journals of biotech, 2010, 155,155-163.
35. Jahangiri, Evaluation of analgesic and anti-inflammatory effect of nanoparticles
of  MgO in mice with and without Ketamine,  journals  of  European medicinal
pharmaceutical science 2013, (20)17, 10-27.
36. vivek  kumar  gupta  and  p.k.  karar,  Preparation  and  optimization  of  process
variables  containing  anti  cancer  drug,  international  journals  of
pharmaceutics(2009),81-91.
37. Peng Guo,Tammy mhsv, Preparation amorphous hydrophobic drug nanoparticles
by  nanoporous  membrane  Implication  in  drug,  journal  of  bioscience  and
bioengineering (2005)18,203,212.
38. Rubina  mara  mainardes,  Nejah  maissar,  Intranasal  delivery of  Zidovudine  by
PLA and PLA-PEG blend nanoparticles, Iinternational journals of pharmaceutics
2010, 290, 137-144.
39. Swarnali  Das,  preeti  k.  suresh,  Design  of  Eudragit  RL 100  nanoparticles  by
nanoprecipitation  method  for  ocular  drug  delivery,  Journal  of  nanomedicine,
2010, 6,318-323.
40. J.  Adlin  jino nesalin  A,  Anton smith,  nanoparticles  an invisible drug delivery
system, review article, journal of pharmacy research, 2011, 373-377. 
41. J.Vandervoot, A.Ludwig, Biocompatible stabilizers in the preparation of PLGA
nanoparticles,  a  factorial  designstudy,  International  journal  of  pharmaceutics
2002, 77-92.
42. T.Vetrichelvan and I.Sowkar Baig, Preparation and in vitro characterization of
slow release Abacavir sulfate nanoparticles in aliginate, International journals of
biological pharmaceutical research 2011, 144-155.
43. N.jawahar,  Preparation and characterization of  PLGA-nanoparticles containing
an anti-hypertensive agent, International journals of pharma tech research 2009,
1-19.
Dept. Pharmaceutics Page 97
Bibiliography
44. Atul Gaikwad, Formulation and invitro characterization of Olymethacrylic acid
nanoparticles containing frusemide, International journals of pharm tech research
2010, 1,300-304.
45. S.Tamizharsi, Formulation and evaluation of lamivudine loaded polymethecrylic
acid nanoparticles, International journals of pharm tech research 2009 3,411-415.
46. Sergio.A,  Design  and  characterization  of  ibuprofen  loaded  nanoparticles,
European journals of pharmaceutics sciences 2005, 125-188.
47. Arvind  gulbak,  Colon  specific  delivery  of  Mesalazine  using  BIO-compatible
polymeric nano-particles2012, 63-72.
48. Rakesh Kumar Sharma, Navneet Sharma, Sudha Rana, Hosakote G. Shivkumar
Solid  Lipid  Nanoparticles  as  a  carrier  of  Metformin  for  Transdermal
Delivery2013, 69-99. 
49. Waree  Tiyaboochai, Formulation  and  evaluation  of  nanoparticles  containing
flutamide, International journals of chemistry tech research 2009, 4, 1331-1334.
50. AMOLKUMAR  LOKHANDE,  SATYENDRA  MISHRA,  RAVINDRA  KULKARNI,  JITENDRA
NAIK*FORMULATION  AND  EVALUATION  OF  GLIPIZIDE  LOADED  NANOPARTICLES  ,
Department  of  Pharmaceutical  Technology,  University  Institute  of  Chemical
Technology, journals of carbohydrate polymers,2010,833-838.
51. Adlinjinonesalinj,  Gowthamarajan  k,  Thommey  P.Thomas,  Amorphous
hydrophobic drug nanoparticles by nanoporous membrane, European journal of
pharmaceutical sceience2012, 65-75.
52. Amrita  dikpati,  Targeted  drug  delivery  system  for  blood  brain  barrier  for
meninigitis,pharkinsonism, Journals of targeted drug release, 2013, 554-573.
53. Sarah D. brown,paul R.Edward ,Gold nanoparticle for the improved anti cancer
drug  delivery  of  the  active  component  of  oxaliplatin,  Journals  of  American
chemical society,2010, 4678-4684.   
54. May D wang,dong m shin, Nanotechnology for targeted cancer therapy,  Journals
of nanoparticle drug 2007, 833-837.  
55. Jayanth  panyam,  Swayam prabha,  Rapid  endo-lysosomal  escape  of  poly  (di-
lactide-co-glycolide) nanoparticles: implication for drug and gene delivery,  the
journals  of  federation  of  American  societies  for  experimental  biology  2002,
1217-1226.
56. Xu wang,dong m shin,  Therapeutic  nanoparticles for  drug delivery in  cancer,
Journals of cancer research clin cancerres 2008,14-1310.
57. P.R.Lockman, M.A.khan, Drug development and industrial pharmacy, Journals of
drug delivery across the blood brain barrier 2002,1-13
Dept. Pharmaceutics Page 98
Bibiliography
58. Brian G.Trewyn, Yannan Zhao, Mesoporus silica nanoparticles based double drug
delivery system for glucose-responsive controlled release of insulin and cyclic
AMP, Journals of american chemical society’s 2009,8398-8400.
59. Sunil  A.Agni  hotri,  M.Aminabhavi,  Recent advances on chitosan-based micro
and nanoparticles in drug delivery, Journals of controlled release 2004, 5-28.
60. C.Schwarz,  Solid-lipid  nanoparticle  for  controlled  drug  delivery,  Journals  of
micro encapsulation 1999, 205-213.  
61. Abdul Karim,  muthanna F, Topical  Piroxicam invitro  release and invitro anti-
inflammatory  and  analgesic  effects  from  palm  oil  esters  based  nanocream,
journals of international journals of medicines, 2009, 163-169.
62. http://en.m.wikipedia.org/wiki/furosemide drug profile.
63. Jasvinder  singh,  sreenivas  pandit,  Vincent  W, Diphtheria,  Toxoid loaded  poly
(caprolactone) nanoparticles moucosal vaccine delivery systems, 2006, 96-105.
64.
65.  
66. Hao S, Wang B, Wang Y,  preparation of Eudragit L 100-55 enteric nanoparticles
by a novel  emulsion diffusion method.  International  journal  of  pharmaceutics
2009.833-838
67. .
68.
69. .
70.
71. .
72. Anna  Lähde,1 Janne  Raula,1 and Esko  I.  Kauppinen Production  of  L-Leucine
Nanoparticles under Various Conditions Using an Aerosol Flow Reactor Method .
2012.
73.  
74. Therapeutic  possibilities  of  ceftazidime  nanoparticles  in  devastating
pseudomonas  ophthalmic  infections,keratitis&Endophthalmitis,journals  of
controlled release,2004,140-146.
75. Rubina mara mainardes,nejah maissar, Intranasal delivery if zidovudine by PLA
and PLA-PEG blend nanoparticles, international journals of pharmaceutics 2010.
76. .
77. Ainly wade and paul J Weller Hand book of pharmaceutical exipients,2 edition
,part-1,royal pharmaceutical society of great Britain,1994,144-209.
78. Ainly wade and paul J Weller Diphtheria toxoid loaded by poly( caprolactone )
nanoparticles as mucosal vaccine delivery system 2006,43-58.
79. .
Dept. Pharmaceutics Page 99
Bibiliography
80. James R.Baker jr,zhengyi cao,nanoparticle response of anti cancer drug improves
therapeutic  response  in  animal  model  of  human  epithelial  cancer,journals  of
research cancerres2005,65-377. 
81.
82. S. Tamizhrasi,  Anil Sorti,  Pravin Gavali, Formulation  and characterization of
polymethacrylic  and  nanoparticles  contain  furosemide, International  Journal  of
PharmTech Research,2010,300-310.
83. Rubina  M.mainardes,Raul  ,nanoparticles  containing  praziquantel  effect  of
formulation  variables  on  size  distribution  ,international  journals  of
pharmaceutics2005,130-144.
84. Rosario  pignatello,nadia  ricupero,preparation  and  characterization  ofEudragit
retard nanosuspension for the ocular delivery of cloricromene,2006,95-125.
85. Umasankar.k,nanoparticular  drug  delivery  system  of  anti  cancer  drug
flutamide,international journals of pharm tech research 2010,155-159.
86. Alica  Fernandez,Anthony.j,preparation  and  characterization  of
polymernanoparticulate  drug  delivery  system  with  simultaneous  incorporation
chemotherapeutic  and  thermo-optical  agents,journals  of  colloids  and
surface,2010,260-267.
87. Amit  .k  goyal,goutam  rath,formulation  and  evaluation  of  chitosan  based
ampicillin  trihydrate  nanoparticles,tropical  journal  of  pharmaceutical
research,2005,24,67-75.
88. Goethamarajan.k  Formulation  and  evaluation  of  nanoparticles  containinf
flutamide,international journal of chemistry tech research 2009,.
Dept. Pharmaceutics Page 100
